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Human Papillomaviruses (HPVs) require terminal differentiation of the host cell 
to produce infectious virions.  The process of viral maturation involves a variety of 
changes in the expression/activity of host proteins that lead to high-level replication of 
the viral genome and expression of the late viral genes.  Although the late promoter 
regions of HPV-16 are still not fully characterized, differentiation-dependent regulation 
of viral genes is thought to involve changes in the binding of host cell transcription 
factors to the viral promoter and regulatory regions.  Currently, little is known about 
specific cellular transcription factors involved in this process. We have used the 
Panomics TransSignal Protein/DNA array to identify changes in the levels of cellular 
transcription factors during methylcellulose-induced differentiation of W12 (20863) cells 
containing HPV-16. We then identified the differentially expressed transcription factors 
that specifically bind to HPV-16 promoters.  We have validated the results obtained from 
the Panomics array by Western blot analysis and with chromatin immunoprecipitation. 
This approach identified approximately thirty transcription factors, many of which 
represent novel viral DNA-host protein interactions.  At present, no treatments exist that 
effectively target and eliminate papillomaviruses (PVs) from infected cells or prevent its 
replication.  We are employing a strategy to prevent virus replication in PV-infected cells 
through the conditional expression of the herpes simplex virus type 1 thymidine kinase 
(TK) gene.  Expression of TK in this system is expected to be triggered by a homologous 
recombination event between the endogenous PV genome and a nonexpressing TK gene 
cassette, which is expected to change the nonexpressing cassette into a form that 
expresses TK.  Various constructs were generated to express the TK in the above manner. 
Transfection of cell lines with a TK nonexpressing plasmid did not result in TK 
production.  However, cotransfection of cell lines with PV plasmids along with the above 
TK construct containing PV sequences resulted in TK expression as shown by Northern 
and Western blot analyses.  We also developed a TK expression cassette utilizing an 
adeno-associated virus (AAV) vector.  Delivery of the cassette by AAV to PV-infected 
cells resulted in TK expression, and ganciclovir treatment resulted in efficient killing of 
these cells. 
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Chapter 1 
 
 
GENERAL INTRODUCTION 
 
 
 
1 
1.1 PAPILLOMAVIRUS LIFE CYCLE 
Papillomaviruses (PVs) are small, nonenveloped, double-stranded DNA tumor 
viruses with genomes of about 8,000 base pairs (zur Hausen, 2002; Hebner & Laimins, 
2005).  PVs are a large and diverse group of viruses, with each virus displaying a tropism 
for certain tissues in a specific vertebrate host.  Some animal PVs, such as bovine 
papillomavirus type 1 (BPV-1), are well characterized and serve as important models of 
papillomavirus biology (zur Hausen, 2002; Hebner & Laimins, 2005).  Nearly 200 types 
of human papillomaviruses (HPVs) have been identified to date and are grouped 
according to their tropism towards specific epithelial cells.  All Papillomaviruses infect 
epithelial cells and all require terminal differentiation of the host cell to produce 
infectious virions (zur Hausen, 2002; Hebner & Laimins, 2005). 
For productive infection to occur, PVs must gain access to the basal epithelium 
through an abrasion or other type of cut in the skin.  For example, HPV types 1 and 2 
must gain access to cutaneous basal epithelium, while types 6 and 16 must gain access to 
mucosal basal epithelium (zur Hausen, 2002; Hebner & Laimins, 2005).  The virus then 
enters the host cell through a mechanism that is not entirely understood, but probably 
involves cellular integrins (zur Hausen, 2002; Hebner & Laimins, 2005).  Following viral 
uncoating and transport to the nucleus, an initial burst of replication brings the viral 
genome to a copy number of about 50 per cell (this copy number is type dependent) (zur 
Hausen, 2002; Hebner & Laimins, 2005).  The viral genomes are maintained episomally 
at these low copy numbers for long periods of time in the basal epithelium, where the 
virus replicates in synchrony with the S-phase of the host cell (zur Hausen, 2002; Hebner 
& Laimins, 2005).  This life cycle is illustrated in Fig. 1. 
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The viral proteins E1 and E2 are expressed at this time and have a number of important 
functions.  E1 is a highly conserved protein across all HPVs, and has been shown to bind 
to the viral origin of replication, and act as a helicase to unwind the DNA in the region 
(zur Hausen, 2002; Hebner & Laimins, 2005; Wilson et al, 2002).  E1 is absolutely 
required for the initiation of replication in all PV types.  The origins of replication of PVs 
contain an E1 binding site that consists of an 18-bp palindromic sequence (Holt & 
Wilson, 1995; Holt et al, 1994; Sun et al, 1996).  E2 also stimulates replication in all PV 
types and is required for the replication of some HPV types (such HPV-16) but not 
required in other types (such as HPV-1) (Gopalakrishnan & Khan, 1994).  There are 
multiple E2 binding sites in the origin of replication of most HPVs and it has been shown 
that E1 and E2 bind cooperatively to this origin in some HPV types (Van Horn et al, 
2001; Chiang et al, 1992).  E2 binding sites are also located in viral promoters, where the 
protein acts to regulate transcription (zur Hausen, 2002; Hebner & Laimins, 2005).  E2 
has been shown to suppress transcription of the viral oncogenes E6 and E7, which is of 
particular importance in HPV related cancers (discussed later).   
Upon the differentiation of the host cell into the spineous layers of the epithelium, 
there is increased expression of E1 and E2 and the virus replicates to high levels (zur 
Hausen, 2002; Hebner & Laimins, 2005).   Transcription of the potent oncoproteins E6 
and E7 is also increased at this stage of differentiation.  E6 interacts with the p53 tumor 
suppressor and targets it for degradation via the proteasome pathway (zur Hausen, 2002; 
Hebner & Laimins, 2005).  E6 also interacts with many other host cell proteins including 
the tumor suppressors hDlg and hScrib (Kiyono et al, 1997; Lee, Weiss & Javier, 1997; 
Nakagawa & Huibregtse, 2000), the replication protein Mcm7 (Kuhne & Banks, 1998; 
4 
Kukimoto et al, 1998), transcriptional factors c-myc and CBP/p300 (Gross-Mesilaty et al, 
1998; Patel et al, 1999; Zimmermann et al, 1999).  E7 binds the RB tumor suppressor, 
preventing the binding of RB to E2F and releasing E2F to promote the progression of the 
cell cycle (zur Hausen, 2002; Hebner & Laimins, 2005).  Normally, the binding and 
sequestration of E2F by the hypophosphorlylated form of RB acts as an important 
checkpoint in the cell cycle.  E7 has also been shown to associate with the cell-cycle 
control protein p21 and histone deacetylase HDAC (Finzer et al, 2001).  E5 is expressed 
in basal and spinous epithelium and may play a role in transformation, although not as 
prominent a role as the E6 or E7 proteins.  It has been shown that E5 can activate 
epidermal growth factor receptor (EGFR) through binding to the 16kD subunit, an 
ATPase protein pump, and initiates biochemical cascades that lead to overexpression of a 
variety of protooncogenes.  Additionally, E5 can inhibit the expression of tumor 
suppressor gene p21 (Tsai & Chen, 2003).  E4 expression is also induced upon 
differentiation into the spinous layer where it has been shown to alter mitotic signals and 
destabilizes keratin (zur Hausen, 2002; Hebner & Laimins, 2005).  Importantly, the major 
and minor capsid proteins L1 and L2 are also produced in the spinous layer.  Mature 
virions are assembled in the granular layers of epithelium and shed with the sloughing of 
the stratum corneum (zur Hausen, 2002; Hebner & Laimins, 2005). 
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1.2 HUMAN PAPILLOMAVIRUSES AND CANCER 
Human Papillomaviruses are associated with over 99% of cervical cancers 
worldwide and have also been associated to a lesser degree with other cancers, such as 
oral cancer (Dell & Gaston, 2001; Flores & Lambert, 1997; Hebner & Laimins, 2005).  
Cervical cancers are strongly linked to certain HPV types, such as types 16, 18, 31, and 
45, which are referred to as high risk HPV types (Dell & Gaston, 2001; Flores & 
Lambert, 1997; Hebner & Laimins, 2005).  Low-risk types, such as types 1, 6, and 11, 
also infect cervical epithelium but are associated with low-grade cervical lesions, and 
almost never with cancer (Dell & Gaston, 2001; Flores & Lambert, 1997; Hebner & 
Laimins, 2005).  The HPV genome often integrates into the host chromosome near the 
viral E2 locus (see Fig 2) in malignancies associated with HPV (Dell & Gaston, 2001; 
Flores & Lambert, 1997; Hebner & Laimins, 2005).  The mechanism for this integration 
is unknown, and it is unclear if the integration event is targeted.  The site of HPV 
disruption in these cancers is almost always in the E2 ORF, but the exact location within 
that region, as well as in the host genome, is seemingly random (Dell & Gaston, 2001; 
Flores & Lambert, 1997; Hebner & Laimins, 2005).  Integration in the E2 ORF prevents 
the expression of E2, and the loss of E2 has been shown to result in transcriptional 
upregulation of the potent oncogenes E6 and E7 (Dell & Gaston, 2001; Flores & 
Lambert, 1997; Hebner & Laimins, 2005).  One hypothesis is that the viral genome 
integrates randomly, but there is a growth advantage in cells which have no E2 
expression and overexpression oncogenes as a result.    
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It should be noted that viral integration prevents productive replication, and represents a 
negative selection for viruses that cause cancer.  This is demonstrated by the fact that a 
majority of people who are persistently infected with HPV do not develop HPV-related 
cancer in their lifetime (Dell & Gaston, 2001; Flores & Lambert, 1997; Hebner & 
Laimins, 2005).  This is consistent with the hypothesis that integration is a low 
probability “accident” which takes years to occur and that the oncogenic potential of 
HPV is greatly increased by its ability to cause persistent infections.  It is known that 
malignancies associated with HPV infection often occur several years after the primary 
infection (Dell & Gaston, 2001; Flores & Lambert, 1997; Hebner & Laimins, 2005).  It is 
also known that HPV lesions may persist for decades without clearance or regression, and 
surgical treatment does not prevent recurrence (Dell & Gaston, 2001; Flores & Lambert, 
1997; Hebner & Laimins, 2005).  At present, no effective treatment is available to target 
and eliminate HPV from persistently infected cells. 
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1.3 PAPILLOMAVIRUS DNA AS A TARGET FOR RECOMBINATION 
During persistent infection, large populations of host cells harbor episomal HPV 
DNA at various copy numbers.  This property can be utilized as a molecular target 
through the use of homologous recombination to trigger the expression of the suicide 
gene Herpes Simplex Virus type 1 Thymidine Kinase (TK).  Homologous recombination 
is just one mechanism by which cells repair double-stranded DNA breaks (DSBs), which 
can be caused by exposure to ionizing radiation, DNA-damaging agents, or stalled 
replication forks (Haber, 1999).   Because DSBs in chromosomes are lethal, cells have 
developed several pathways that compete for repair of these double-stranded breaks, one 
of which is homologous recombination.  Homologous recombination can occur through a 
process known as gene conversion (Haber, 1999).  Classically, this process begins with 
the resection of the 5’ end of the DNA at the DSB.  The resulting 3’ overhangs can then 
invade the donor strand through extensive base-pairing to complimentary sequences in 
the donor strand (Haber, 1999).  This strand invasion is catalyzed by the RAD51 protein.  
RAD52 strongly stimulates strand invasion, possibly by binding to DSBs and recruiting 
RAD51 to these sites (McIlwraith et al, 2000).  The single-stranded binding protein RPA 
also strongly stimulates single-strand annealing by RAD51, possibly by removing 
secondary structure in the 3’ overhang which might repress RAD51 binding (McIlwraith 
et al, 2000).  Following strand invasion, DNA polymerization occurs at the 3’ end of the 
invading DNA strand using the donor strand as a template.  The newly synthesized strand 
of DNA then anneals to homologous sequences on the other end of the DSB to accurately 
repair the junction at the site of the break (Haber, 2000).  This process of strand exchange 
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forms a Holliday structure that may result in crossing over when the structure is resolved 
(Haber, 2000). 
Single-stranded annealing, like gene conversion, begins with the resection of the 
5’ ends surrounding the break.  Unlike gene conversion, resection of the 5’ ends at the 
double-stranded break exposes small homologous sequences originally flanking the 
break.  These sequences then anneal as single-stranded DNA and are ligated together to 
create a deletion at the site of the double-stranded break (Haber, 2000).  Non-homologous 
end joining also competes with homologous recombination for repair of double-stranded 
breaks.  In this process, free ends resulting from a double-stranded break are joined 
through one of multiple mechanisms, none of which involves extensive homology 
between the sequences.  The result is that the break is repaired, but the junction is often 
inaccurately reconstituted and frequently contains deletions, misalignments, and additions 
of small sequences (Haber, 2000).   
 It should be noted that homologous recombination occurs frequently between 
episomal sequences.  This was demonstrated in numerous experiments in which plasmids 
containing homologous sequences were cotransfected into mammalian cells and 
recombination between the plasmids was detected using antibiotic resistance, southern 
blot, and restriction enzyme analysis.  Intramolecular and intermolecular homologous 
recombination between identical sequences co-transfected into immortalized cells occurs 
in roughly 0.2% to 1% of recovered plasmids when the recombination donor and target 
sequences are co-transfected at nearly equimolar ratios (Nickoloff & Reynolds, 1990; 
Thyagarajan et al, 1996; Rouet et al, 1994; Seidman, 1987).  Consistent with the idea that 
DSBs induce homologous recombination; the frequency of recombination can be 
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dramatically increased by linearizing one or both of the plasmids undergoing 
recombination near the sites of recombination prior to transfection.  Cutting one plasmid 
increases the recombination frequency 2-7 fold (Ayers et al, 1985) and cutting both 
fragments near the recombination sites results in frequencies of 10% to 30% (Ayers et al, 
1985; Rouet et al, 1994).  Homologous recombination between replicating plasmids 
occurs continuously over a 48-hour period (Ayers et al, 1985), which argues that 
increased recombination frequencies could be seen over extended periods of time.  If self-
replicating plasmids are allowed to recombine for a one-month period, over 50% of the 
plasmids undergo a type of irreversible intramolecular homologous recombination 
(Kitamura et al, 1990).  These frequencies are in contrast with chromosomal homologous 
recombination, which occurs with frequencies of less than 1 in 10 million cells in the 
absence of a DSB and in only 0.2-1% of cells where a break has been induced at the site 
of recombination in the chromosome (Taghian & Nickoloff, 1997).  This is of particular 
interest because, as mentioned previously, papillomavirus replicates as an 
extrachromosomal element in the host cell. 
11 
1.4 ALTERNATIVE POLYADENYLATION SIGNAL USAGE 
In order to utilize recombination to trigger the expression of the suicide gene, TK, 
a very tightly regulated expression system must be developed.  We have chosen to 
regulate the expression of TK through alternative splicing and polyadenylation signal 
usage.  The expression of many natural genes is known to be regulated by alternative 
poly(A) site selection and this selection is known to be effected by both the position and 
relative strength of the poly(A) sites (reviewed in Edwards-Gilbert et al, 1997 ). Among 
identical poly(A) signals, the 5’ site is favored over a more distal downstream site 
(Demone & Cole, 1988).  Also, when a strong poly(A) site precedes a weak one by a 
short distance, less than 5% of the processed mRNAs terminate at the weak site (Batt et 
al, 1994).  It is also known that poly(A) site usage can be affected by surrounding splice 
sites.  Cooke et al (1999) have shown that a 5’ splice site, if not followed by a 3’ splice 
site, can interfere with downstream polyadenylation.  Poly(A) site usage in alternatively 
spliced regions can also be suppressed through exon skipping of the poly(A) signal.  
Exon skipping has been shown to decrease when the 5’ splice site following the skipped 
exon is strengthened, but increases when the 5’ splice site is weakened or eliminated 
(Kuo et al, 1991).  
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1.5  HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE 
HSV-1 Thymidine Kinase (TK), in contrast to mammalian thymidine kinases, 
converts the nontoxic nucleoside analogue ganciclovir to a monophosphorylated 
nucleotide analogue.  In the cell, the monophosphorylated form of ganciclovir is further 
phosphorylated to the triphosphate form.  This form of ganciclovir is incorporated into 
the growing strand of DNA during replication by cellular polymerases.  Incorporation 
causes premature chain termination, preventing replication of the host genome and results 
in the loss of viability of the host cell (Salomon et al, 1995).  HSV-1 TK is, therefore, an 
effective suicide gene when used in conjunction with ganciclovir and has been used 
successfully in many gene therapy approaches.  Notably, Caruso et al (1995) have used 
TK under the transcriptional control of a truncated form of the HIV-1 LTR to induce TK 
expression in transfected tissue culture cells expressing the LTR-specific viral elongation 
factor Tat.  They found that the process of transfecting the TK expression construct and 
treating the transfected cells with acyclovir (a drug similar to ganciclovir) was effective 
at killing cells expressing Tat, with minimal effects on non-expressing cells (Caruso et al, 
1995).  This conditional expression of TK is useful in only fractions of HIV-1 infected 
cells, however, because both the expression of Tat and the transcriptional processivity 
mediated by Tat can vary greatly in infected cells in vivo, with some infected cells having 
no measurable Tat activity (Adams et al, 1999).  Although the concept investigated by 
Salomon et al, Caruso et al, and others shows great efficacy, it is not based on a 
molecular target that must be present in all infected cells.  Obviously, a viral genome 
must be present in infected cells during productive, latent, or persistent infections. 
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1.6  ADENO-ASSSOCIATED VIRUS AS A VECTOR 
 AAV is a small (4.7 Kb) single-stranded DNA virus that is being increasingly 
used as a gene-delivery vector (Hirata & Russell, 2000; Sun et al, 2000; Xiao et al, 
1998).  AAV has many attractive features for use in delivering recombination-dependent 
TK expression cassettes.  Of particular relevance is its ability to efficiently infect many 
types of dividing and non-dividing cells, the low immune response generated to it, and its 
persistent expression of transgenes (Sun et al, 2000).  Importantly, AAV is highly 
recombinogenic both at the terminal repeats that flank the genome and throughout the 
genome (Hirata & Russell, 2000; Sun et al, 2000).  Though no extrachromosomal gene 
replacement studies have been performed, chromosomal gene replacement studies using 
AAV by Hirata and Russell (2000) show a 3-4 log increase in recombination frequencies 
over those achieved by conventional methods.  Wild-type AAV-2 has also been found in 
significant numbers of cervical epithelial cells from patients (Venturoli et al, 2001), 
indicating that AAV can infect the same types of cells that high risk HPV types infect.  
Raft culture studies of human epithelial cells have demonstrated that AAV and HPV can 
also co-infect the same cell (Meyers et al, 2001).  This is evidence that recombinant AAV 
could effectively deliver a recombination-dependent TK expression cassette to a patient 
in vivo.  As mentioned previously, recombinant AAV can transduce many types of 
human cells both in vivo and in vitro, but AAV does not efficiently transduce many 
transformed rodent cell lines (Hansen et al, 2001; Russel et al, 1995).  Unfortunately, 
these same cell lines harbor the BPV episomaly at high copy number.  Pretreatment of 
these cells with the ribonucleotide reductase inhibitor hydroxyurea (HU) increases 
transduction efficiency dramatically (Hansen et al, 2001).  Although the mechanism is 
14 
still unknown, this increase in transduction efficiency may be due to alteration of 
trafficking in these cell lines and not due to the classical HU activities such as S-phase 
arrest and/or induction of DNA repair functions (Hansen et al, 2001; Russel et al, 1995). 
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1.7  HPV-16 TRANSCRIPTION 
As mentioned previously, Papillomavirus requires terminal differentiation of the 
host cell to produce infectious virions.  The process of viral maturation involves a 
regulated and orderly increase in expression of at least six proteins (zur Hausen, 2002; 
Hebner & Laimins, 2005).  Amazingly, HPV-16 only expresses one transcription factor, 
E2, and E2 activity is dispensable for the upregulation of gene products upon 
differentiation.  It is likely that HPV has evolved to utilize naturally occurring changes in 
host cell transcription factor expression and activation to express viral genes in an 
ordered cascade.  This stratagem enables HPV-16 to regulate the expression of at least 
eight products from a small genome comprised of about 90% open reading frames.  To fit 
so many ORFs in such a small genome, HPV-16 makes use of a complex pattern of 
alternative splicing, alternative polyadenylation signal usage, alternative translational 
start sites, and multiple promoters, as illustrated in Fig. 3 (zur Hausen, 2002; Hebner & 
Laimins, 2005). 
 
Early p97 promoter 
The most active and best characterized promoter of HPV-16 is the p97 promoter 
(major transcriptional start site at base pair 97).  This promoter is responsible for the 
expression of E6, E7 and probably responsible for E1, E2, E4 and E5 as well (zur 
Hausen, 2002; Hebner & Laimins, 2005).  There is uncertainty about many of these genes 
because the 5’ end of many mRNA species have not been fully mapped, and complex 
splicing patterns as well as alternative translational start sites make it difficult to 
determine which transcripts express specific proteins.  Through alternative splicing, the 
16 
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 p97 promoter may also express L1 and L2.  It has been found that p97 activity increases 
1.5 to 3 fold upon differentiation of the host cell (Apt et al, 1996; Grassmann et al, 1996; 
Yukawa et al, 1996) and correlates to increases in expression of early genes.  As 
mentioned previously, E6 and E7 expression is dramatically induced upon differentiation 
(zur Hausen, 2002; Hebner & Laimins, 2005).  It remains unclear how an increase in E2 
can accompany an increase in E6 and E7, which has been shown to be suppressed by E2 
expression from the p97 promoter in undifferentiated cells.  Also, L1 and L2 expression 
is undetectable before differentiation, while easily detectable afterwards (zur Hausen, 
2002; Hebner & Laimins, 2005).  This is likely more than a 1.5-3 fold increase in 
transcription.  While this could be a result of altered splicing patterns or polyadenylation 
signal usage, it argues that other promoters may be utilized to express these late genes. 
It is clear that understanding how p97 promoter activity changes during 
differentiation is crucial to understanding the life cycle of the virus.  Many common 
cellular transcription factors such as AP1 (Apt et al, 1993; Chan et al, 1990), NF1 (Ai et 
al, 1999), Oct-1 (Chan et al, 1990), SP1 (Flores et al, 1997), and YY1 (Ciccolini et al, 
1994) have been shown to activate or inhibit the p97 promoter, as shown in Fig. 3.  The 
expression or activity of many of these common transcription factors are not known to 
change dramatically during differentiation.  A few differentiation specific transcription 
factors, such as CDP (Lee & Haber, 2001) and EPOC-1 (Sen et al, 2004), have also been 
identified and may play a role in transcriptional regulation during differentiation.  It has 
also been found that ratios of SP1 and SP3 change subtly during differentiation and this 
change can regulate expression to some degree (Apt et al, 1993).  Interestingly, linker 
scanning analysis of the promoter of the closely related virus HPV-31 demonstrated that 
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many regions are important to the differentiation dependent induction of expression 
(Ozbun & Meyers, 1999; Pattison et al, 1997).  This is strong indication that small 
changes in the activity of many transcription factors may act together to upregulate the 
p97 promoter during differentiation.  Interestingly, the transcriptional changes seen in the 
studies of factors involved in p97 transcription do not represent the “on/off” switching 
seen in the late genes, L1 and L2.  This is yet another indication that there is an additional 
level of regulation, and possibly another promoter for the late genes. 
 
Late promoter(s) of HPV-16 
It is likely that HPV-16 requires promoters other than the p97 promoter to express 
its full complement of proteins.  The presence of other promoters could explain the 
tightness of the regulation of products such as L1 and L2.  The 5’ end of the mRNA that 
expressed L1 and L2 from wild-type infections has not been fully mapped due to low 
expression, cell type dependence, and interference from other transcripts.  A number of 
regions from bp 200-700 in HPV-16 have been found to have weak transcriptional 
activity and may act as late promoters (Fig. 4) (Grassmann et al, 1996; Ozbun & Meyers, 
1999; Rosensteirne et al, 2003).  These promoters are named for their transcriptional start 
sites and include p200, p215, p310, p455, p480, p542, and p670.  Interestingly, many of 
these promoters are not associated with the classical TATAA and CAAT sequences 
typical of eukaryotic promoters (Fig. 4).  The p542 promoter has been shown to be 
downregulated by the differentiation-dependent factor hSkn-1a, in a closely related virus,  
19 
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and is probably downregulated upon differentiation (Ozbun & Meyers, 1999).  The p670 
promoter has been shown to be upregulated 5-12 fold upon cellular differentiation, and 
may be responsible for the expression of the late genes (Grassmann et al, 1996; 
Rosensteirne et al, 2003).  There are no sites for the viral E2 gene in these promoter 
regions and transcription is likely to be entirely dependent on host cell transcription 
factors (zur Hausen, 2002; Hebner & Laimins, 2005).  The cellular transcription factors 
that bind these promoters are very poorly defined to date, and remain an interesting target 
for further research.   
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1.8  THESIS OUTLINE 
 Chapter 1 provides a summary of the work described herein as well as a general 
overview of papillomavirus biology, with particular emphasis on the life cycle of the 
virus.  It has been well established that the life cycle of papillomavirus is intimately 
linked to the differentiation of the host cell, although few of the molecular mechanisms 
that control the life cycle have been elucidated.  The functions of various viral proteins 
are also described in Chapter 1, with particular emphasis on the early proteins.  The viral 
E6 and E7 proteins are the major viral oncoproteins and have been linked to cancer 
progression.  The E1 and E2 proteins are involved in control of viral replication and 
episomal maintenance.  The episomal status of the viral genome makes the genome a 
target for homologous recombination, which is known to occur with high frequency 
between episomal DNAs.  We have exploited this unique aspect of papillomavirus 
biology in developing a recombination based approach to eliminate papillomavirus 
infection.  The approach utilizes alternative polyadenylation signal usage to regulate the 
suicide gene Herpes Simplex Virus type I Thymidine Kinase (HSV-TK) on a rAAV 
delivered cassette.  Relevant background information about alternative polyadenylation 
signal usage, the HSV-TK suicide gene, and rAAV are provided in Chapter 1.  As 
mentioned previously, the complete viral life cycle requires terminal differentiation and 
yet few of the molecular mechanisms that control this have been characterized.  It is 
known that there are subtle changes in transcription from the major viral promoter (p97) 
of human papillomavirus type 16 during differentiation.  It is thought that one or more 
late promoters are dramatically upregulated during differentiation and these may be 
responsible for expression of early as well as late genes.  As the viral E2 protein is 
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dispensable for this upregulation, this is likely due to changes in cellular transcription 
factor binding during differentiation.   
 Chapter 2 describes experiments to identify transcription factors with altered 
binding to the promoters of HPV-16 during cellular differentiation.  These factors are 
likely to control transcription from viral promoters and may be at least partially 
responsible for the induction of late promoter activity during host cell differentiation.  
About 35 transcription factors were identified using the methods described, many of 
which were not previously known to bind HPV-16.  Some of these were characterized in 
greater depth to validate the technique.  
Chapter 3 describes the design and testing of a recombination-based approach to 
eliminate papillomavirus infection.  This concept exploits the ability of the episomal 
papillomavirus genome to undergo homologous recombination and utilizes alternative 
polyadenylation to regulate the expression of HSV-TK.  This approach was effective in 
eliminated cells infected with Bovine Papillomavirus type I (BPV). 
Chapter 4 provides a general discussion of the research described within.  Results 
of the characterization of transcription factors binding to HPV-16 during cellular 
differentiation are briefly reviewed, and the many unanswered questions that arose from 
this work are introduced.  Many experiments are then described to address these 
unanswered questions, such as determining the functional significance of these 
interactions.  Next, the rationale behind the design of the TK-expression cassette utilized 
in the recombination based approach to eliminate papillomavirus infection is explained 
and supported by detailed case-by-case analysis.   
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Some of the results of these experiments are reviewed and their implications are 
discussed.  Additionally, future goals in the use of recombination to eliminate viral 
infections, such as the adaptation of the concept to HPV, are outlined. 
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Chapter 2 
 
CHARACTERIZATION OF TRANSCRIPTION FACTOR 
BINDING TO HUMAN PAPILLOMAVIRUS TYPE 16 DNA 
DURING CELLULAR DIFFERENTIATION 
 
Work described in this section is being published in the Journal of Virology (May 2006, 
Volume 80) with authors A. Carson and S. A. Khan. A. Carson performed all the 
experiments described in this section 
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2.1 INTRODUCTION 
Human Papillomaviruses (HPVs) are small, nonenveloped, double-stranded DNA 
tumor viruses that are associated with over 99% of cervical cancers world-wide (Dell & 
Gaston, 2001; Flores & Lambert, 1997; Hebner & Laimins, 2005).  More than 100 types 
of HPVs have been identified to date.  Certain mucosatropic HPVs such as types 6 and 11 
are rarely seen in cervical cancers, whereas other types, such as 16, 18, 31, and 45 are 
associated with a much higher risk of cervical malignancy (Dell & Gaston, 2001; Flores 
& Lambert, 1997; Hebner & Laimins, 2005).  The HPV genome often integrates into the 
host chromosome at the viral E2 locus in these malignancies, and the resulting cells do 
not express the viral regulatory protein E2 (Dell & Gaston, 2001; Flores & Lambert, 
1997; Hebner & Laimins, 2005).  The loss of E2 activity results in the overexpression of 
the high-risk HPV-16 E6 and E7 oncoproteins, which promote cell growth by a variety of 
mechanisms including the inactivation of the functions of the cellular tumor suppressor 
proteins p53 and pRB (Ciccolini et al, 1994; Scheffner et al, 1993).  Even though HPV-
positive cancer cells do not produce infectious virions, understanding the life-cycle of 
HPVs including the regulation of viral gene expression is fundamental to a better 
understanding of HPV-associated malignances.  Upon infection of the human host, HPVs 
gain access to the basal epithelium and early genes are transcribed as soon as 8 hours post 
infection (Ozbun, 2002).  The early genes E1 and E2 are required for viral replication 
(Sverdrup & Khan, 1994), allowing viral DNA to be maintained episomally at low copy 
numbers in the basal epithelium (Dell & Gaston, 2001; Flores & Lambert, 1997; Hebner 
& Laimins, 2005).  Virion production requires terminal differentiation of the host cell 
during which the virus replicates to high copy numbers, produces the capsid proteins L1 
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and L2, and mature virions are formed (Dell & Gaston, 2001; Flores & Lambert, 1997; 
Hebner & Laimins, 2005).  The virus that is shed can then reinfect the basal epithelium or 
spread to new hosts.  Many regulated changes in viral gene expression are thought to 
occur during cellular differentiation, viral DNA amplification and virion production.   
The HPV-16 early promoter, p97, is involved in the transcription of the E6, E7 
and other viral genes (Dell & Gaston, 2001; Flores & Lambert, 1997; Hebner & Laimins, 
2005).  Ubiquitous transcription factors (TFs) such as AP-1, NF1, Oct1, and SP1 have 
been shown to activate transcription from the p97 promoter (Apt et al, 1996; Chan et al, 
1990; Chong et al, 1991; Gloss & Bernard, 1990).  The YY1 transcription factor has been 
shown to both activate and repress transcription from this promoter (Don et al, 1994). 
Also, expression from the p97 promoter has been shown to increase slightly during 
cellular differentiation (Apt et al, 1993; Grassmann et al, 1996; Yukawa et al, 1996).  
The p670 promoter, which likely corresponds to the late HPV-16 promoter, is also 
thought to be activated during differentiation resulting in the expression of the late genes 
L1 and L2 (Grassmann et al, 1996; Rosenstierne et al, 2003).  A number of promoters in 
HPV-16 have been identified with transcription start sites between positions 200 to 700 
that may also play a role in late gene expression.  Some of these promoters have been 
shown to be upregulated during differentiation in HPV-16 (Grassmann et al, 1996; 
Rosenstierne et al, 2003), while others are downregulated during differentiation of 
closely-related viruses (Ozbun & Meyers, 1999).  A few differentiation-specific 
transcription factors such as CDP (Ai et al, 1999; O’Conner et al, 2000; Pattison et al, 
1997), and EPOC-1 (Yukawa et al, 1996), have also been identified and may play a role 
in transcriptional regulation of papillomaviruses during differentiation.  Other specific 
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transcription factors such as Sox5 and SRY have previously been shown to regulate 
transcription of closely-related HPVs (Spink & Laimins, 2005).  The ratios of SP1 and 
SP3 factors are also known to change during differentiation and this in turn may also 
regulate HPV-16 gene expression (Apt et al, 1996).  Linker scanning analysis of the early 
promoter of the high-risk HPV-31 has shown that many TFs and cis-acting sequences are 
important in differentiation-dependent induction of gene expression (Sen et al, 2002; Sen  
et al, 2004).  Similarly, a deletion analysis of the late promoter of HPV-31 has revealed 
many regions and protein factors that are also important in the activation of late promoter 
during differentiation (Spink & Laimins, 2005). It has also been shown that activation of 
the late HPV-31 promoter during differentiation is independent of viral genome 
amplification (Bodily & Meyers, 2005; Spink & Laimins, 2005).   
In this study, we have investigated the changes in the levels of cellular 
transcription factors during differentiation to identify factors that specifically bind to the 
HPV DNA. For this, we used a Panomics TransSignal array containing 345 binding sites 
for transcription factors. By competition analysis, we identified the transcription factors 
that specifically bind to the HPV-16 DNA, including the upstream regulatory region as 
well as the region containing the late promoter.  We found that the binding activity of 36 
factors that interact with HPV sequences is altered during differentiation.  
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We confirmed these results by Western blot analysis and also showed by chromatin 
immunoprecipitation (ChIP) assays that many of the above transcription factors bind to 
the HPV-16 DNA in vivo. Our data identified several differentially expressed 
transcription factors that were previously known to bind to HPV-16 DNA during 
differentiation as well as a number of novel factors that were not previously known to 
interact with the HPV-16 DNA.  
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2.2  MATERIALS AND METHODS 
Cell line 
The HPV-16 cervical cell line 20863 (a clonal population of W12 generated from 
a low-grade squamous intraepithelial lesion) (Fehrmann & Laimins, 2003) containing 
episomal HPV-16 DNA was obtained from the laboratories of Drs. Margaret Stanley and 
Paul Lambert (Medical Research Council, UK and University of Wisconsin, USA, 
respectively). The cell line was maintained in E medium with 10% FBS in the presence 
of murine 3T3 J2 fibroblast feeder cells previously treated with mitomycin C (Fehrmann 
& Laimins, 2003). The 20863 cell line was induced to differentiate by treatment with 
1.68% methylcellulose and 10µM C8 for 48 hours.  Before DNA isolation, fibroblast 
feeders were removed with versene (phosphate-buffered saline with 0.5 mM EDTA, 
Gibco BRL). 
 
Panomics array 
To investigate the relative binding of human transcription factors (TFs) to their 
unique consensus sequences, we used the TransSignal protein/DNA combo array with 
spin column preparation (Cat# MA1215) from Panomics (Redwood City, CA).  Array 
analysis was performed as per manufacturer’s instructions using nuclear extracts from 
20863 cells before and after differentiation.  Nuclear extracts were prepared using the 
Panomics nuclear extraction kit (Cat# AY2002) as per manufacturer’s instructions.  
Briefly, cells were allowed to swell in a hypotonic buffer to disrupt the plasma 
membrane. The nuclei were then lysed in a high-salt buffer as described in the Panomics 
nuclear extraction kit.  Protein was quantified by Bradford assay (Bio-Rad Laboratories, 
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Hercules, CA).  Ten micrograms of nuclear extract from 20863 cells isolated before and 
after differentiation were incubated with 10 µl TransSignal probe mix (Panomics) for 30 
minutes at 15o C.  The TransSignal probe mix contains 345 biotin-labeled double-
stranded DNA oligonucleotides representing consensus binding sites for approximately 
320 transcription factors.  This is due to the fact that more than one binding site is 
included for some TFs, and in some cases more than one TF binds to the same binding 
site.  Twenty microliters of 1X Column Incubation buffer (Panomics) was then added, 
transferred to a TransSignal spin column, and incubated on ice for 30 minutes.  The Spin 
column was then centrifuged at 7,000 rpm for 30 seconds at 4o C in a refrigerated 
microfuge and the flow through discarded.  Next, 600 µl of Column Wash buffer was 
added and incubated on ice for 10 minutes.  The Spin column was then centrifuged again 
at 7,000 rpm for 30 seconds at 4o C and the flow through discarded.  The washings with 
Column Wash buffer was repeated three additional times.  Next, 60 µl of Column Elution 
buffer was added to the spin column and incubated at room temperature for 5 minutes.  
Oligonucleotides specifically bound to the TFs present in the nuclear extracts were then 
eluted by centrifugation for 1 minute at 10,000 rpm in a microfuge.  The eluted oligos 
were then denatured by boiling for 3 minutes followed by a quick chill on ice.  These 
oligos were added to 5 ml of Hybridization buffer (Panomics) and hybridized to the 
TransSignal Array membrane containing oligonucleotides (representing 345 consensus 
binding sites for TFs) overnight at 42o C.  The blot was then washed at 42o C for 20 
minutes with 50 ml of Hybridization Wash I and then washed at 42o C for 20 minutes 
with 50 ml of Hybridization Wash buffer II.  The membrane was then blocked for 15 
minutes at room temperature with 20 ml of Blocking buffer (Panomics).  Streptavidin-
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HRP conjugate was then added to the blocking buffer at a 1:1,000 dilution and incubated 
for 15 minutes to allow binding to the biotinylated oligonucleotides.  The membranes 
were then washed three times for eight minutes each with Wash buffer (Panomics).  The 
membrane was then incubated with 20 ml Detection buffer at room temperature for 5 
minutes. In order to visualize spots, the membrane was overlaid with a mixture of 200 µl 
of solution I, 200 µl of solution II, and 1.6 ml of solution III (all from Panomics) and 
incubated at room temperature for 5 minutes.  The resulting spots were visualized on 
Kodak X-Omat Blue XB-1 film (Kodak, Rochester, NY) and scanned using a Typhoon 
scanner.  Spots were identified and quantified using the Image Quant software and the 
data compared using Excel software.  In competition experiments, either 20 µg of 
pUC19/HPV-16 DNA or 4 µg of a 1.7-kb PstI fragment of HPV-16 (nt 7005-7816/1-875 
that includes all the known promoters) were mixed with 5 µl of the TransSignal probe 
mixture followed by incubation with the nuclear extracts made from differentiated 20863 
cells.  This represents approximately 20-fold molar excess of each competitor over the 
oligonucleotides in the probe mixture (Panomics, personal communication).  The 
resulting array was then compared to the data obtained using differentiated 20863 nuclear 
extracts with no competitor HPV-16 DNA.  The signals obtained in the presence of the 
above competitors were then compared with those obtained in the absence of any 
competitor.  Since signal strength varies moderately in each array due to a variety of 
factors, the total signal strength for each array obtained using the Image Quant software 
were normalized to each other.  On an average, the variation in total signal strength 
between arrays was less than 1.4-fold.  Only factors found to be differentially bound upon 
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differentiation and competed off by both full-length HPV DNA and HPV promoter 
regions are reported. 
 
Sequence analysis 
In order to further characterize potential TF binding sites identified by the 
Panomics array, known TF binding sites were obtained from the TRANSFAC database 
(Wingender et al, 2000) and compared to the HPV-16 sequences.  The binding sites 
reported by TRANSFAC facilitated the identification of putative TF binding sites in the 
HPV-16 regulatory regions and also helped in the design of primer sequences used in the 
ChIP assays. 
   
Chromatin immunoprecipitation (ChIP) assays 
ChIP assays were performed using Upstate Chromatin Immunoprecipitation 
Assay kit (Upstate, Lake Placid, NY) as per manufacturer’s instructions.  Briefly, 106 
cells were trypsinized and cross-linked using formaldehyde, and sonicated with 16 pulses 
at setting #7 on an Ultrasonics model W-225R sonicator (Plainview, NY).  This is 
expected to generate DNA fragments of an average length of 500-bp.  Lysates were then 
diluted 10-fold in ChIP Dilution Buffer and incubated with salmon sperm DNA/Protein 
A-agarose slurry for 30 minutes at 4ºC with agitation.  Cell debris and non-specifically 
interacting proteins were pelleted by centrifugation for 1 minute at 4ºC and the 
supernatant was collected.  An aliquot of this supernatant was used as a “No IP” control 
in the ChIP assays.  Cleared lysates were then incubated overnight along with 20 µl of the 
appropriate primary antibodies with gentle agitation.  All antibodies were purchased from 
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Santa Cruz Biotechnology (Santa Cruz, CA).  Complexes were then immunoprecipitated 
with Protein-A agarose and washed as per manufacturer’s instructions.  Proteins were 
then uncrosslinked from DNA by heat and removed using phenol/chloroform extraction.  
DNA was then recovered by ethanol-precipitation and subjected to PCR analysis using 
various HPV-16 specific primer sets.  Primer pair I amplifies a region from nt 7,054 to nt 
7,221, which is upstream of the established p97 promoter and includes the NFATx site.  
Primer pair II amplifies a region from nt 7661 to nt 7853, which includes part of the p97 
promoter and is close to the NF1 and Pax5 sites.  Primer pair III amplifies a region from 
nt 267 to nt 440, which may be involved in late gene expression and is near two C/EBPα 
sites and one C-Myb site.  Primer pair IV amplifies a region from nt 651-816, which may 
be involved in late gene expression and is in the vicinity of WT1 and Stat5 binding sites.  
β-actin primers amplify a region of the  β-actin open reading frame with no known 
transcription factor binding activity.  The sequences of the various prime pairs were as 
follows: 
I (HPV 7054-7221):  5’gattgaaggccaaaccaaaa3’ &   5’caagcacatacaagcacatacaaa3’ 
II (HPV 7661-7853):  5’taaatcactatgcgccaacg3’   &    5’cacacacccatgtgcagttt3’  
III (HPV 267-440):  5’gagatgggaatccatatgctg3’ &    5’caggacacagtggcttttga3’ 
IV (HPV 651-816):  5’cagctcagaggaggaggatg3’ &   5’gcccattaacaggtcttcca3’ 
β-actin:  5’gccatgtacgttgctatcca3’     &   5’aggaaggaaggctggaagag3’ 
Quantitative PCR analysis of DNA obtained from these ChIPs was performed using the 
QuantiTect SYBR Green PCR kit from Qiagen (Valencia, CA) as per manufacturer’s 
instructions.  As a control, HPV primers set I was used to amplify HPV DNA from the 
“No IP” samples described above using the QuantiTect SYBR Green PCR kit.  The 
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signals from ChIP amplifications were then normalized to this control HPV amplification 
to account for unequal cell counts, lysis efficiency, or other differences in sample 
processing.  The annealing temperature for all PCRs was 58o C. 
 
Western blot analysis 
Western blot analyses were performed as described (Sambrook et al, 1989).  Whole cell 
lysates were prepared from 20863 cells by incubation in a buffer containing 50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100 with 2 mM Na3VO4 and 50 mM NaF 
added as phosphatase inhibitors and one pellet of Complete Protease Inhibitor Cocktail 
(Roche, Mannheim, Germany) per 10 ml.  Lysates were cleared by centrifugation for 1 
minute at 7,000 rpm in a refrigerated microcentrifuge and quantified by Bradford assay.  
All antibodies were purchased from Santa Cruz Biotechnology, with the exception of 
GAPDH, which was purchased from Chemicon (Temecula, CA).  Primary rabbit 
polyclonal antibodies were used at the following dilutions: anti-C/EBPα, 1:1,000 
dilution; anti-C-Myb, 1:200 dilution; anti-NF1, 1:1,000 dilution; anti-NFATx (NFATc3), 
1:200 dilution; anti-Stat5, 1:100 dilution; anti-WT1, 1:1200 dilution.  Primary mouse 
monoclonal antibodies for Pax5 were used at a dilution 1:200, for GAPDH at a dilution 
of 1:30,000, and for keratin K10 at a dilution of 1:1,000.  All primary antibodies were 
incubated for two hours in TBS-T (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% 
Tween 20) with various blocking agents at room temperature.  C/EBPα, C-Myb, 
GAPDH, Stat5, WT1, and keratin K10 primary antibodies were incubated in 5% dry 
milk.  Anti-NFATx antibodies were incubated in 1% dry milk, while anti-NF1 and anti-
Pax5 antibodies were incubated in the presence of 5% BSA.  Following primary antibody 
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incubation, blots were successively washed thrice with TBS-T for 5, 10 and 15 minutes 
with gentle agitation.  Secondary anti-rabbit-HRP conjugate was then added at a dilution 
of 1:3,000 for all blots utilizing rabbit primary antibodies including anti-C/EBPα, anti-C-
Myb, anti-GAPDH, anti-NF1, anti-NFATx (NFATc3), anti-Stat5, and anti-WT1.  
Secondary anti-mouse-HRP conjugate was added at a dilution of 1:5,000 to Pax5, 
GAPDH, and keratin K10 blots since they utilized mouse primary antibodies.  The blots 
were incubated for one hour at room temperature in TBS-T containing the same blocking 
agent as that used with the primary antibodies.  Blots were again successively washed for 
5, 10, and 15 minutes and proteins were visualized using the ECL plus Western Blotting 
Detection System (Amersham, Buckinghamshire, UK) as per manufacturer’s instructions. 
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2.3  RESULTS 
The 20863 cell line containing HPV-16 can be differentiated by methylcellulose and 
C8 treatment   
 
Prior to their use in our experiments, we confirmed the presence of episomal 
HPV-16 DNA in the W12 clone 20863 by isolation of the Hirt fraction (Hirt, 1967)) 
followed by Southern blot analysis (data not shown). To differentiate 20863 cells, we 
used a combination of methylcellulose and C8 treatment.  Methyl cellulose is an 
established method to differentiate keratinocytes ((Fehrmann & Laimins, 2003).  C8 is a 
synthetic diacylglycerol that activates the protein kinase C pathway to induce a more 
complete differentiation (Sen et al, 2002; Sen et al, 2004).  These treatments have been 
used together to induce differentiation in HPV-positive cells (Sen et al, 2002; Sen et al, 
2004).  Treatment of the 20863 cell line with methylcellulose and C8 resulted in 
induction of the differentiation marker keratin K10 as shown by Western blot analysis 
(Fig. 5), demonstrating that differentiation has been induced. 
 
Identification of Transcription Factors with Altered Expression/Activity during 
Differentiation that bind to HPV-16 DNA 
We utilized a Panomics TranSignal array to compare the binding of TFs present 
in nuclear extracts of undifferentiated and differentiated 20863 cells to oligonucleotides 
representing 345 different consensus sequences.  This analysis identified binding 
increases of over 2-fold for 64 consensus sequences and a decreases of over 2-fold for 86 
sequences (data not shown).  This corresponds to changes in the binding activity of 148 
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different TFs upon differentiation (the ISRE and CBF/NF-Y factors have two binding 
sites each on the array).   
 In order to identify TFs that show differences in their activity during 
differentiation and that also bind to HPV-16 sequences, a series of competition assays 
were performed.  In one experiment, a pUC19 plasmid containing the full-length HPV-16 
genome (Sverdrup & Khan, 1994) was added in a 20-fold molar excess over the target 
oligonucleotides during incubation with the nuclear extracts.  The binding of TFs to the 
exogenously added HPV-16 DNA is expected to compete with their binding to the 
biotinylated target oligonucleotides.  This would result in a loss/reduction in signal 
obtained upon hybridization of the labeled oligonucleotides to the array (see Materials 
and Methods). The binding of 48 transcription factors to the oligonucleotides was 
competed off (greater than 4-fold reduction in probe binding to the array). These data 
suggested that upon differentiation the binding of 38 TFs to cloned HPV-16 is increased 
while that of 9 TFs is decreased.  We also used a 1.7-kb PstI fragment of HPV-16 (nt 
7005-7816/1-875) which includes both the p97 and late promoters of HPV-16 as a 
competitor in the above assays.  The data obtained from the array showed that the above 
fragment competed for the binding of 31 TFs that showed increased binding and 5 that 
showed decreased binding upon differentiation to the probe oligonucleotides. The cloned 
pUC19/HPV-16 DNA contains both specific and “non-specific” sequences, and the “non-
specific” sequences also serve as a negative control in these experiments.  Note that most 
of the TFs competed off by pUC19/HPV-16 DNA were also competed off by the known 
HPV-16 regulatory regions present in the 1.7-kb PstI fragment.  This provides a 
validation of the technique and shows that most of the TFs specifically interact with the
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TABLE 1.  Changes in transcription factor binding to HPV-16 promoters during 
cellular differentiation 
 
TF   Fold Increase*  TF  Fold Decrease 
AP-2   6.39    AP-1  2.93  
ATF2              +++     MyoG  6.76  
C/EBPα  7.61     GRE  14.6  
CACC              +++    Pbx1  2.04  
CCAAT   +++    TREF1, 2 33.0  
C-Myb              +++   
CP1              +++   
CPIB              +++   
EBP40, 45        10.1   
ETF              +++   
GAG   5.87   
GBF1, 2, 3, HY5      +++   
GKLF   3.03   
H4TF-1  +++   
HIF-1               51.4   
KTP              +++   
Lactoferrin BP     +++ 
LCR-F1      +++ 
MT-box  5.75 
MTF              +++ 
NF1              +++ 
NFAtx              +++ 
NF-kB   3.83 
NF-Y              +++ 
Pax5              +++ 
PCF   2.03 
PEBP              +++ 
RFX1, 2, 3   20.3 
RIPE3a   +++ 
RORE   2.56 
Snail              +++ 
Stat5   3.83 
TFE3L    +++ 
WT1                25.3 
YY1   2.38 
 
*-When TF binding was not detectable in undifferentiated cells but present upon 
differentiation, an infinity value was assigned by the software, these are labeled (+++). 
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HPV-16 regulatory regions. Based on the above experiments, the TFs that specifically 
bind to a region of HPV-16 that contains known promoter regions are listed in Table 1.  
 
The HPV-16 promoter regions have identifiable consensus sequences for novel TFs 
whose expression is altered during differentiation   
 
Many TFs identified in the above experiments were previously not known to bind 
to the HPV-16 promoters and may represent novel interactions. Therefore, we analyzed 
the sequence of the PstI fragment of HPV-16 (nt 7005-7816/1-875) for the presence of 
consensus binding sites for known human TFs in the TRANSFAC database (Wingender 
et al, 2000).  A number of binding sites for both TFs that are known to interact with 
HPV-16 DNA as well as novel factors that represent previously unknown interactions 
with the viral DNA were identified in this region, including several NF1 binding sites, 
two sites for C/EBPα, and single sites for C-Myb, Stat5, Pax5, WT1, and NFATx (Fig. 
6). 
 
The levels of several transcription factors that bind to HPV-16 sequences are 
increased during differentiation 
 
The Panomics TranSignal array detects changes in the binding of known 
transcription factors to their binding sites. While this would generally indicate altered 
expression of TFs during differentiation, it may also be due to changes in the activity of 
TFs (for example, due to protein modifications).  Therefore, we also carried out Western 
blot analysis for a few representative TFs to determine if the increase in their binding 
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activity during differentiation as determined by using the Panomics array is correlated 
with increased protein levels.  Fig. 7 is a representation of three independent experiments  
and shows that the levels of C-Myb, NF1, Pax5 and WT1 were dramatically increased 
upon differentiation, while the levels of C/EBPα, and NFATx showed only a modest 
increase.  These results showed that the expression of several TFs that bind to HPV-16 
promoter/regulatory regions is upregulated during differentiation. 
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Binding of transcription factors to the HPV-16 DNA in vivo  
Chromatin immunoprecipitations (ChIPs) experiments were carried out to 
determine whether some of the TFs identified in the above screen bind to the HPV-16 
DNA in vivo.  For this, proteins bound to DNA in the 20863 cell line with or without 
differentiation were cross-linked with formaldehyde and specific DNA-protein 
complexes isolated using antibodies against selected transcription factors as described in 
Materials and Methods. The DNA bound to proteins was recovered and the bound HPV 
sequences were identified by standard PCR analysis as shown in Fig. 8A.  In order to 
quantify the amount of HPV DNA present, the above samples were also analyzed by 
quantitative PCR using primer pairs near the predicted binding sites for the above 
transcription factors (see Fig. 6).  The relative amount of bound DNA is expected to 
represent the relative levels of specific TFs bound to the viral DNA in differentiated vs. 
undifferentiated cells.  The data, which are averages of three experiments, showed that 
C/EBPα, C-Myb, and NF1 bound to the HPV-16 DNA in differentiated cells to 
substantially higher levels than in undifferentiated cells with increases of 8-, 71-, and 9.7-
fold, respectively (Fig. 8).  NFATx, Pax5, Stat5, and WT1 showed a more moderate 
increase in binding to HPV sequences upon differentiation (2.6-, 1.9-, 1.5-, and 1.5-fold, 
respectively).  In control experiments, the use of template DNA immunoprecipitated  
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using antibodies specific to various TFs failed to amplify the β-actin gene (Fig. 8C).  In 
another control, we used anti-MBP antibodies in the above experiments and the “mock-
precipitated” DNA was used as the template for PCR amplification using HPV-16 primer 
pairs I, II, III and IV described above. No amplified DNA was obtained (Fig. 8C).  The 
above ChIP assays identified TFs that bind to HPV-16 regulatory regions in vivo and also 
revealed the TFs whose binding to the viral DNA is increased upon differentiation. 
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2.4 DISCUSSION 
We have used the W12 clone 20863 to identify changes in TF binding to HPV-16 
promoter/regulatory regions during host cell differentiation using the Panomics 
TransSignal array.  The 20863 cell line harbors HPV-16 episomally and can be induced 
to differentiate (Fig. 5).  Our analysis identified changes (≥2-fold difference) in the 
binding of TFs to 150 consensus sequences during differentiation out of the 345 
sequences present on the array.  These changes in TF binding may either represent their 
altered expression, activity, or both.   Competition experiments using the Panomics 
TransSignal arrays revealed 38 TFs present in differentiated 20863 cells with increased 
binding to the pUC19/HPV-16 DNA, while 9 TFs in differentiated cells showed a 
decrease in binding to this DNA (Table 1).  Since TF consensus sequences may also be 
present randomly in the HPV-16 genome or the vector pUC19 sequence and may have no 
role in transcription, we also used a 1.7-kb PstI fragment of HPV-16 (nt 7005-7816/1-
875) which contains all the known viral promoter/regulatory elements as competitor in 
the above experiments.  These results identified 31 TFs with increased binding to the 
above 1.7-kb region while 5 TFs showed reduced binding upon differentiation (Table 1).  
These TFs were a subset of those identified when the pUC19/HPV-16 DNA was used as 
the competitor.  We then analyzed the above 1.7-kb region for the presence of putative 
binding sites for known TFs using the TRANSFAC database (Wingender et al, 2000).  A 
majority, but not all of the TFs identified by the Panomics array have identifiable binding 
sites in this region (Fig. 2 and data not shown).  The putative binding sites of many of the 
above TFs are located in regions associated with late promoters and these factors may 
play a role in controlling late gene expression.  These poorly characterized promoters 
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(with transcription start sites located between nt 200 and 700 of the HPV-16 genome) are 
thought to be dramatically upregulated during host cell differentiation as compared to the 
slight upregulation of the p97 promoter (Grassmann et al, 1996; Rosenstierne et al, 
2003).  A plausible hypothesis is that this upregulation of the late promoters is due to 
increased binding of stimulatory TFs (including those identified in this study) during 
differentiation.  It is interesting, therefore, that while approximately similar number of 
TFs show increased and decreased binding to their consensus sequences during 
differentiation (65 and 85, respectively), the vast majority of TFs that interact with the 
regulatory regions of HPV-16 show increased binding activity during differentiation 
(Table 1).  Many of these factors are known to stimulate transcription and may play a role 
in the upregulation of late promoters during the viral life cycle.  
 Several of the TFs found to be upregulated during differentiation in this study 
such as C/EBPα and NF1 have previously been shown to affect HPV-16 transcription 
(Apt et al, 1993; Chong et al, 1991; Dong et al, 1994; Hadaschik et al, 2003).  Such 
known factors provide a validation of the approach we have used in this study which also 
identified several TFs not previously implicated in the regulation of HPV gene 
expression.  Our data also expand the knowledge of previously known interactions 
between HPVs and TFs.  For C/EBPα, this represents the first in vivo evidence that this 
factor binds to the HPV-16 DNA and the first demonstration that this binding and protein 
expression increases during differentiation.  The dramatically increased DNA binding 
activity of NF1 during differentiation is most likely due to a significant increase in its 
expression as shown by Western blot analysis (Fig. 7).  NF1 has been shown to 
upregulate the p97 promoter through its multiple binding sites located in this region (Apt 
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et al, 1993; Chong et al, 1991).  Many other TFs such as Stat5 have been loosely 
associated with HPV infection or HPV-related malignancies but were not known to be 
directly involved in transcription of the viral genome (Chang & Laimins, 2000; Havard et 
al, 2005; Rocha-Zavaleta et al, 2004; Nees et al, 2001).  The activity of Stat5 protein was 
consistently increased in both oligonucleotide binding as determined by the Panomics 
array as well as in vivo binding to the HPV-16 genome as assayed by ChIP (Table 1 & 
Fig. 8).  Our results further support a role for Stat5 in HPV gene expression during viral 
maturation or virus-induced carcinogenesis.   
 We have identified several TFs in this study and provide the first in vivo evidence 
for their binding to HPV-16 DNA as well as changes in their binding to the viral genome 
during differentiation.  For example, binding of C-Myb, Pax5, NFATx and WT1 to the 
HPV-16 regulatory region represents novel interactions.  The Wilm’s tumor gene product 
(WT1) is known to be associated with tumor progression (Lee & Haber, 2001), and its 
interaction with the HPV-16 promoter regions could represent an additional mechanism 
by which this factor may promote carcinogenesis.  TFs such as C-Myb, NFATx, and 
Pax5 are known to play important roles in development and/or differentiation (Serfling et 
al, 2000; Hirokawa et al, 2003; Rushton et al, 2003).  Expression of the C-Myb and Pax5 
protein was not detectable in the 20863 epithelial cells before differentiation, but was 
induced during differentiation as shown by Western blot analysis (Fig. 7).  While 
Western blot analysis showed a limited increase in the levels of NFATx during 
differentiation (Fig. 7), its DNA binding activity was significantly increased as 
determined by the Panomics array and ChIP assays (Table 1 & Fig. 8).  This could be due 
to changes in nuclear localization since the NFATx activity is known to be regulated in 
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this manner (Serfling et al, 2000).  It is likely that HPV-16 and possibly other HPVs may 
have adapted to utilize many cellular transcription factors involved in differentiation and 
development to regulate their gene expression during host cell differentiation in epithelial 
cells.   
 The relative changes in TF levels or activity during differentiation as identified by 
the Panomics array, ChIP assay, and Western blot analysis were variable.  These 
variations may represent differences in the sensitivity of the assays, increased activity 
resulting from protein modifications and/or subcellular localization, or due to some 
unknown factors.  Since we have validated our data by carrying out detailed analysis of a 
select number of TFs identified using the Panomics array, it increases the confidence that 
other TFs identified using this array may also interact with HPV-16 sequences and their 
expression/activity may also be altered during differentiation.   
Taken together, our results as well as previous studies by other investigators 
suggest that HPVs may have evolved to utilize many changes in transcription factor 
binding and expression during differentiation to achieve tight regulation of the late viral 
genes.  Many such factors are involved in differentiation, development and/or 
carcinogenesis and should be targets for further study.  In the future, we plan to confirm 
interactions of additional TFs with HPVs and determine the functional significance of 
many of the novel transcription factors in HPV gene expression and HPV-associated 
disease.  
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Chapter 3 
 
A DNA RECOMBINATION-BASED APPROACH TO 
ELIMINATE PAPILLOMAVIRUS INFECTION 
 
Work described in this chapter was published in Gene Therapy (2005, Volume 12, pages 
534-540) with authors A. Carson, Z. Wang, X. Xiao, and S. A. Khan.  Z. Wang and X. 
Xiao provided plasmids into which the expression cassettes were inserted, prepared the 
recombinant AAV used in this study and took part in many helpful discussions. A. 
Carson performed all the other experiments described in this section 
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3.1  INTRODUCTION 
Papillomaviruses (PVs) are small, nonenveloped, double-stranded DNA tumor 
viruses (Dell & Gaston, 2001; Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 
2003; zur Hausen, 2002).  During productive infection, the virus gains access to the basal 
epithelium where the viral DNA replicates to a low level of approximately 50 copies per 
infected cell (Dell & Gaston, 2001; Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 
2003; zur Hausen, 2002).  Virion production requires terminal differentiation of the host 
cell during which the virus replicates to high levels, produces the capsid proteins L1 and 
L2, and mature virions are formed (Dell & Gaston, 2001; Stubenrauch & Laimins, 1999; 
Fehrmann & Laimins, 2003; zur Hausen, 2002).  The shed virions then reinfect the basal 
epithelium or they can infect new hosts. PVs infect many different species of animals in 
nature, and to date more than 100 types of human papillomaviruses (HPVs) have been 
identified (Dell & Gaston, 2001; Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 
2003; zur Hausen, 2002).  Certain mucosatropic HPVs such as types 6 and 11 cause low-
grade cervical lesions, while others such as HPV-16, HPV-18, HPV-31, and HPV-45 are 
strongly associated with cervical cancer and other anogenital cancers (Dell & Gaston, 
2001; Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 2003; zur Hausen, 2002).  
The HPV genome often integrates into the host chromosome at the viral E2 locus in these 
malignancies, and the resulting cells do not express the viral regulatory protein E2 (Dell 
& Gaston, 2001; Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 2003; zur Hausen, 
2002).  The loss of E2 activity results in the overexpression of the viral E6 and E7 
oncoproteins, which inactivate the functions of the cellular tumor suppressor proteins p53 
and RB, respectively (Dell & Gaston, 2001; Stubenrauch & Laimins, 1999; Fehrmann & 
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Laimins, 2003; zur Hausen, 2002).  The E6 and E7 proteins also target several other 
cellular pathways that contributes to their oncogenic potential (Dell & Gaston, 2001; 
Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 2003; zur Hausen, 2002).  
Malignancies associated with HPV infection usually occur several years after the primary 
infection and the oncogenic potential of HPVs is greatly increased by its ability to cause 
persistent infections. Although low-risk HPVs such as types 6 and 11 are rarely 
associated with cancer, they often cause painful long-term infections (Dell & Gaston, 
2001; Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 2003; zur Hausen, 2002).  
Also, cutaneous HPVs such as types 1 and 2 can cause benign lesions that can be painful 
or cosmetically unacceptable and require medical treatment (Dell & Gaston, 2001; 
Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 2003; zur Hausen, 2002). 
Untreated, the above types of lesions may persist for decades without clearance or 
regression, and surgical treatment does not prevent recurrence. (Dell & Gaston, 2001; 
Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 2003; zur Hausen, 2002).  At 
present, no effective treatment is available to target and eliminate HPV from persistently 
infected cells. During the persistent state, large population of host cells harbor episomal 
HPV DNA. This allows a potential opportunity to disrupt the episomal HPV genome by 
an approach involving homologous recombination. In contrast to the chromosome, 
homologous recombination between episomal DNA elements occurs more frequently. 
Intermolecular homologous recombination between related plasmids cotransfected into 
immortalized cells occurs in roughly 0.2−1% of recovered plasmids (Ayers et al, 1985; 
Thyagarajan et al, 1996).  These frequencies have been shown to be even higher in a 
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bovine papillomavirus (BPV)-based mammalian plasmids over extended time periods 
(Kitamura et al, 1990). 
In this study, we have developed a DNA recombination-based approach for the 
conditional expression of the suicide HSV-1 thymidine kinase (TK) gene. The gene 
cassette is designed to express TK, through homologous recombination, only in cells that 
contain BPV DNA. Transfection of the DNA cassette resulted in the expression of TK in 
cell lines containing the BPV DNA, whereas little or no expression was observed in cells 
lacking the BPV sequences. We also utilized an adeno-associated virus (AAV)-TK 
cassette for the specific expression of the HSV-1 TK gene in BPV-1-containing cells. In 
combination with ganciclovir (GCV) therapy, this novel approach in gene therapy may 
allow elimination of PV infections by targeting the viral DNA specifically in infected 
cells. 
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3.2  MATERIALS AND METHODS 
Oligonucleotides 
The following primers were used for the amplification of DNA for cloning:  
TK-forward:GGAGATCTATGCCCACGCTACTGCGG 
TK-reverse:GGTCTAGAGGACGCGTTCAGTTAGCCTCCCCCAC 
Polyoma-forward:ACGCGTGCTATGTTGACCGCTTTG 
Polyoma-reverse:TCTAGACTCCTACAGTTTGTTTTGTG 
BPV-forward:CCTTTAGACACCCTTGAAACTC 
BPV-reverse:GGAATTCGACCACAGCTACATGTCAGG 
3S3-forward:GGGGATCCTGCAGGTAAGTCCGATGACACTACTACTACACC 
3S3-reverse:GACCGTCTATATAAACCCGC 
3S5A-forward:GGCTGATTATGATCCTCTAGAGTCGCAG 
3S5A-reverse:GGTGATCAGGTTTTCCCAGTCACGACGTTGTAAAAC 
3S5B-forward:GGTGATCACTGCGACTCTAGAGGATCATAATCAGCC 
3S5B-reverse:GGGGTGATCAGAAGCGGAAGAGTCTAGATCCTACAGTTTG 
The following oligonucleotides were used to create 3' ss II and the FLAG epitopes:  
3' ss II-top:CTAGCCTAACCATGTTCATGCCTTCTTCTTTTTCCTACAGA 
3' ss II-bottom:GATCTCTGTAGGAAAAAGAAGAAGGCATGAACATGGTTAGG 
FLAG-top:AATTACCACCATGGACTACAAAGACGACGACGACAAAG 
FLAG-bottom:AATTCTTTGTCGTCGTCGTCTTTGTAGTCCATGGTGGT 
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DNA constructs 
A truncated version of the TK ORF (Salomon et al, 1995) was PCR amplified 
using primers TK-forward and TK-reverse. The ORF was then isolated as a BglII/MluI 
fragment. The weak PV poly(A) site was PCR amplified from the wild-type A2 strain of 
PV using primers polyoma-forward and polyoma-reverse. This poly(A) site was then 
isolated as a MluI/XbaI fragment. These two fragments were then ligated into BglII/XbaI-
digested plasmid pSG5 (Stratagene) in a three-way ligation to create pSTP. The BPV-1 
genome from nt 4501 to base 6647 containing portions of the L1 and L2 ORFs was PCR 
amplified using primers BPV-forward and BPV-reverse. This region was then isolated as 
an EcoRI fragment and cloned into the MfeI site of pSTP to create plasmid S2.1TP. The 
SV40 poly(A) site of pSG5 was isolated as a 160-bp BamHI/XbaI fragment, the ends 
were filled-in with Klenow fragment of DNA polymerase I and ligated into the filled-in 
NheI/ClaI site within the 2.1-kb BPV sequence described above. The NheI/ClaI digestion 
within the BPV-1 sequence resulted in the loss of 46 bp from the BPV sequence between 
the BPVa and BPVb regions. An EcoRI fragment containing two SV40 poly(A) sites in 
the forward orientation along with the adjacent BPVa and BPVb sequences was then 
isolated and cloned into the MfeI site of pSTP to create SS2TP. The SV40 poly(A) trimer 
was released from plasmid pUCA15 (Batt et al, 1994) via HpaII/BglII digestion. A 
double-stranded oligonucleotide with BglII and NheI ends containing the 3' ss II sequence 
along with the above SV40 poly(A) trimer was ligated into the NheI/ClaI site of the 2.1-
kb BPV fragment described above in a three-fragment reaction. These elements were 
then isolated as an EcoRI fragment and cloned into the MfeI site of pSTP to create 
plasmid 3S3. A region of 3S3 was PCR amplified using primers 3S3-forward and 3S3-
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reverse to introduce the 5' ss II upstream of the BPVb region. The amplified product was 
then isolated as a BamHI fragment and ligated into BamHI-digested 3S3. This resulted in 
the addition of the 5' ss II to 3S3, generating plasmid 3S35. A 378-bp region of the 3S35 
plasmid was deleted from the BPVa region by digestion with NheI and AflII, filling in the 
ends with Klenow, and self-ligation to create 3S35-del. A synthetic FLAG epitope was 
created by hybridizing oligonucleotides FLAG-top and FLAG-bottom with EcoRI ends, 
and ligating the DNA upstream of the TK ORF into the EcoRI site of 3S35-del to create 
3S35-dF. The same FLAG epitope was also inserted into the EcoRI site of S2.1TP to 
create S2.1TP-F. We also generated the AAV-3S5 vector for delivery of the TK cassette 
into murine cells. This involved cloning of a TK cassette similar to 3S35-dF, except 
containing a single SV40 poly(A) site in place of a trimer, into the AAV vector pXX. For 
this, two regions of 3S35-dF cassette were amplified, one containing the SV40 promoter 
and the BPVa region (using primers 3S5A-forward and 3S5A-reverse) and the second 
containing one copy of the SV40 poly(A) signal, BPVb region, the TK ORF and the 
polyomavirus poly(A) signal (using the primers 3S5B-forward and 3S5B-reverse). The 
first region was then isolated as a BclI/BglII fragment and the second as a BclI fragment. 
These two fragments were then simultaneously ligated into the BglII sites of plasmid 
pXX containing the AAV inverted terminal repeats to generate the AAV-TK plasmid 
pXX-3S5. 
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Virus production 
The AAV used was serotype 2. The recombinant viral stocks were produced 
according to the adenovirus-free, three plasmid cotransfection method (Zolotukhin et al, 
1999).  Briefly, the AAV-TK vector plasmid pXX-3S5 was cotransfected into human 293 
cells with the helper plasmids pXX2 (Zolotukhin et al, 1999) supplying rep-cap function 
and pXX6, a truncated adenovirus plasmid supplying E2a, E4, and VA RNA. Cells were 
harvested 48 h after transfection, and then frozen and thawed four times. The viral 
particles were purified from the crude lysate using an FPLC-Heparin column (Zolotukhin 
et al, 1999).  Virus particle numbers were determined by quantitative DNA dot-blot 
analysis (Sambrook et al, 1989).  
 
Transfections 
COS-1 cells were transfected with the lipofectamine reagent (Gibco). 
Transfections were performed according to the supplier's instructions in 60 mm dishes 
seeded with 2−3 106 cells, 3 g total DNA, and 30 l lipofectamine reagent per 
transfection. 
 
Infections 
BPV-137 or C-127 cells were plated 1 day prior to infection at a density of 2−3 
105 cells per 60 mm dish. The next morning, cells were treated with 3 mM hydroxyurea 
for 2−3 h in complete DMEM media. Following this treatment, cells were washed and 
complete media containing 5 109 viral particles was added. Infections were allowed to 
proceed overnight, the cells were again washed, and complete media were added. 
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 Western blots 
Western blots were performed as described (Sambrook et al, 1989).  Primary 
rabbit polyclonal anti-TK antibodies were purchased from William Summers at Yale 
University and used at a 1:400 dilution. Primary anti-FLAG M2 monoclonal antibodies 
were purchased from Sigma and used at a 1:1000 dilution. 
 
RNA isolation and northern blots 
RNA was isolated using the ULTRASPEC RNA Isolation Kit from Biotecx 
according to the manufacturer's instructions. Northern blot analysis was performed by 
standard methods (Sambrook et al, 1989).  The radiolabeled probes were prepared by 
random primer labeling of restriction enzyme fragments or whole plasmids (Sambrook et 
al, 1989).  The blots were stripped by boiling in 25 mM phosphate buffer (pH 7.2) with 5 
mM EDTA and 1% SDS. 
 
GCV treatment 
BPV-137 cells were plated 1 day prior to infection at a density of 2−3 105 cells 
per 60 mm dish (in triplicate). The next morning, cells were treated with 3 mM 
hydroxyurea for 2−3 h in complete DMEM media. Following this treatment, cells were 
washed and complete DMEM medium containing 5  109 viral particles was added. 
Infections were allowed to proceed overnight, the cells were again washed, and complete 
DMEM medium was added (Mizuno et al, 1998).  GCV was added to a concentration of 
50 M and selection was allowed to proceed for 4 days (Fukui et al, 2001). 
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3.3  RESULTS 
Development of Recombination-Dependent TK Expression Cassettes 
We developed a strategy for the expression of the HSV-1 TK gene conditional 
upon its recombination with PV sequences. The desirable features of this gene cassette 
are that it must not express TK, but in the presence of PV sequences in the cell, it should 
undergo homologous recombination, leading to the expression of the TK gene. The DNA 
sequence encoding the amino-terminal region of TK has been shown to act as a weak 
promoter in some tissues (Salomon et al, 1995).  As TK expression must be tightly 
regulated in this system, we utilized an amino-terminal-deleted version of TK in which 
this promoter is deleted. This TK deletion retains the ability to phosphorylate GCV 
(Salomon et al, 1995).  We developed several TK expression cassettes as shown in Fig. 9. 
In preliminary studies, we first utilized a strategy involving the use of alternative 
polyadenylation (poly(A)) sites to restrict TK expression prior to recombination. We 
generated the SS2TP expression cassette to take advantage of the known criteria for 
poly(A) site selection (for a review see Edwards-Gilbert, Veraldi & Milcarek, 1997). In 
this expression cassette, an intron containing nt 4501−6647 of the BPV genome 
consisting of parts of the L2 and L1 ORFs was inserted upstream of the TK open-reading 
frame (ORF) and the weak late poly(A) site of polyomavirus (Batt et al, 1994). Two 
poly(A) regions that contain both the early and late poly(A) sites of SV40 were then 
inserted into the middle of the above BPV sequence such that the upstream BPVa region 
consisted of 926 bp, while the downstream BPVb region contained 1169 bp (Fig. 9). We 
anticipated that transcripts from this expression cassette would primarily  
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terminate at the strong upstream SV40 poly(A) sites. Western blot analysis using protein 
extracts from COS-1 cells transfected with SS2TP showed that TK expression from this 
plasmid was nearly as high as in cells transfected with the positive control plasmid 
S2.1TP that is expected to express high levels of TK (Fig. 10). A faster-migrating band in 
the Western blot presumably corresponds to a breakdown product of TK. A plasmid 
containing the GFP gene was used as a negative control and it did not express any TK 
(Fig. 10). In order to further characterize expression from the SS2TP plasmid, a series of 
Northern blot analyses were performed using total RNA isolated from COS-1 cells 
transfected with various plasmids. When the Northern blot was probed with the 3S35 
plasmid DNA, a single band of approximately 1400 nt was observed in cells transfected 
with SS2TP (Fig. 11a). COS-1 cells transfected with the control TK expression plasmid 
S2.1TP also contained a single transcript of approximately 1400 nt (Fig. 11a). The 
transcript present in the GFP plasmid presumably corresponds to the GFP transcript, 
which also contains 5' and 3' regions that are common to all the plasmids. The blot was 
then stripped and reprobed with the TK ORF to identify transcripts containing TK 
sequences (Fig. 11b). The TK probe hybridized to the same RNA species in cells 
transfected with S2.1TP and SS2TP plasmids that were detected using the 3S35 probe, 
demonstrating that this transcript corresponds to the TK mRNA (Fig. 11b). No specific 
band was detectable when the same blot was reprobed with BPV sequences (data not 
shown). Taken together, the results of Northern blot analyses indicated that only one 
transcript was produced by the S2.1TP and SS2TP expression cassettes, which contains 
the TK ORF but no BPV sequences. Furthermore, the approximate size of this transcript  
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is consistent with termination of transcription at the polyomavirus poly(A) site, and little 
or no termination at the SV40 poly(A) sites. 
We hypothesized that TK expression by the SS2TP plasmid may be due to the fact 
that the SV40 poly(A) sites closely follow a 5' splice site (5' ss I) in this plasmid, and the 
unspliced transcript may not be efficiently terminated/polyadenylated. To eliminate this 
possibility, we inserted a 3' splice site (3' ss II) upstream of the SV40 poly(A) sites. We 
also replaced the SV40 poly(A) dimmer with an SV40 poly(A) trimer to possibly 
increase the relative strength of the polyadenylation signal. This trimer contains three 
head to tail copies of a 237 bp segment of SV40 containing both the early and late 
poly(A) signals (Maxwell et al, 1989).  The resulting construct (3S3 − Fig. 9) showed 
greatly reduced TK expression as assayed by Western blot analysis (Fig. 10). However, 
TK expression was not completely eliminated in the presence of this plasmid (Fig. 10 and 
data not shown). Northern blot analysis of these transfectants indicated that two 
transcripts of approximately 1400 and 400 nt were produced by this expression cassette 
(Fig. 11a). The larger transcript hybridized to the TK ORF but not to the BPV sequences 
(Fig. 11b and data not shown). The smaller transcript contained neither TK nor BPV 
sequences, consistent with it being an RNA species resulting from the usage of the SV40 
poly(A) sites that will contain only 5' and 3' untranslated regions (Fig. 11b and data not 
shown). Together, these results suggest that the upstream SV40 poly(A) site is used 
predominantly in this construct, but the downstream polyoma poly(A) site is also used to 
a limited extent resulting in low-level TK expression. 
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It is likely that low-level TK expression from the 3S3 plasmid is due to alternative 
splicing from the 5' ss I to the 3' ss I (Fig. 10) by a mechanism similar to exon skipping. 
As the skipped exon in this system had no 5' splice site following the 3' ss II and the 
SV40 poly(A) signals, we introduced another 5' splice site (5' ss II) at this position, 
generating the 3S35 cassette (Fig. 9). When this plasmid was transfected into COS-1 
cells, TK expression was undetectable by Western blot analysis (Fig. 10). Northern blot 
analysis revealed that the 400 nt transcript first seen with 3S3 is more abundant with 3S35 
(Fig. 11a). No transcripts complementary to the TK or BPV L1 probes were observed 
upon transfection of 3S35 (Fig. 11b and data not shown), demonstrating that the upstream 
SV40 poly(A) sites were exclusively used in this construct. 
 
The ability of homologous recombination to regulate TK expression 
The 3S35 plasmid was designed to express TK when this construct is introduced 
into PV-infected cells but not in uninfected cells. The regulation of TK in this system is 
expected to depend on homologous recombination between segments of the endogenous 
PV genomes and PV L1/L2 sequences present in the 3S35 construct. To assess this 
possibility, we modified 3S35 to create the plasmid 3S35-dF. First, a sequence encoding 
the FLAG epitope was added upstream of the TK ORF to generate a FLAG-TK fusion to 
increase the sensitivity of the Western blots. Second, the overall size of the expression 
cassette was reduced so that it can be incorporated into an AAV vector for studies 
described later. This was carried out by reducing the size of the BPVa region from 926 to 
548 bp. The deletion reduces the total length of BPV sequences (BPVa+BPVb) from 2098 
to 1720 bp. Rubnitz and Subramani (1984) have shown that the length of homology 
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between repeated sequences in a transfected plasmid is proportional to the recombination 
frequency between these sequences, so long as both sequences are over 200 bp in length. 
The above deletion is expected to cause a small decrease in the recombination frequency 
between the endogenous PV genome and 3S35-dF as compared to the full-size 3S35 
construct. Fig. 12 shows that the smaller 3S35-dF expression cassette does not express 
TK when cotransfected along with pUC19 DNA into COS-1 cells. The positive control 
plasmid S2.1TP-F containing a FLAG−TK fusion expressed high levels of TK (Fig. 12). 
To determine if 3S35-dF can express TK in the presence of BPV DNA, COS-1 cells were 
cotransfected with 3S35-dF and a BPV-1-containing plasmid. Western blot analysis 
indicated that cotransfection of 3S35-dF with either circular or linear BPV-1 DNA 
resulted in TK expression (Fig. 12). There was a slight increase in TK expression in the 
presence of linear BPV-1 target, consistent with the possibility that homologous 
recombination of 3S35-dF with linear BPV-1 DNA is more efficient. 
 
The use of AAV to deliver a TK expression cassette to papillomavirus-infected cells 
For a therapeutic expression cassette to be useful in vivo, an effective vector must 
be used for delivery. We, therefore, tested whether AAV, which is capable of infecting 
mucosal cells (such as those harboring PVs) can be used for the conditional expression of 
the TK gene. We created a modified version of the 3S35-dF expression cassette, 3S5, in 
which two of the SV40 poly(A) sites were deleted from the SV40 poly(A) trimer to 
further reduce the size of the cassette. Our studies had suggested that splice site  
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placement, rather than the relative strength of the poly(A) site, largely determines the 
polyadenylation pattern in these expression cassettes (data not shown). Therefore, we 
postulated that there would be little or no effect of reducing the SV40 trimer to a 
monomer on TK expression. The 3S5 plasmid was found not to express TK as 
determined by Western blot analysis when introduced into PV-negative COS-1 cells by 
transfection (data not shown). We then incorporated the 3S5 cassette into the AAV 
vector, generating AAV-3S5 (Fig. 13a). The AAV-3S5 vector was used to infect BPV-
137 cells, a C127 mouse fibroblast cell line that harbors about 1000 BPV-1 genomes per 
cell (McBride & Howley, 1991) or the parental C127 cells at a multiplicity of infection of 
10 000 vector genomes per cell. As the vast majority of viral particles are not infectious 
in mouse cells (unpublished data), this corresponds to a transducing units of 
approximately 10 per cell. Since human cell lines containing stably replicating BPV-1 
DNA are not available, we utilized the murine BPV-137 cell line in these experiments. 
This cell line was chosen because it harbors a BPV-1 mutant at a high copy number, 
which might increase the frequency of recombination over a cell line containing wild-
type BPV-1. Since murine cell lines are poorly permissive for AAV infection, cells were 
pretreated with hydroxyurea to increase the transduction efficiency (Hansen et al, 2001).  
Hydroxyurea treatment at these low levels is thought to alter intracellular trafficking and 
enhance conversion of single-stranded AAV DNA to double-stranded genomes (Hansen 
et al, 2001).  Also, cell cycle arrest is not seen at these low levels of HU (data not 
shown). Following infection, TK expression was assayed by Western blot analysis. To 
reduce the background signals, cell lysates were first immunoprecipitated with an anti-
Flag M2-agarose affinity gel, and then subjected to 
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Western blot analysis using anti-TK polyclonal antibodies. As shown in Fig. 13b, BPV-
137 cells infected with AAV-3S5 expressed TK, while the parental BPV-negative cell 
line C-127 did not. This result is similar to that obtained in the cotransfection assay using 
TK cassettes along with a BPV-1 plasmid (Fig. 12). These results demonstrate that TK 
expression can be induced by DNA recombination in BPV-positive cells upon delivery of 
a nonexpressing cassette by an AAV vector. 
 
The use of rAAV and ganciclovir to eliminate PV-infected cells 
Although TK expression was detectable through the use of immunoprecipitation 
followed by Western blot analysis, we wished to determine whether TK levels were 
sufficient to eliminate PV-infected cells upon treatment with GCV. For this, BPV-137 
cells were either mock infected or infected with AAV-3S5. The cells were then treated 
with GCV for a period of 4 days. Cells were harvested using trypsin and attached cells 
were counted. As shown in Fig. 14, both infected and uninfected BPV-137 cells rapidly 
proliferated without GCV treatment. BPV-137 cells that were uninfected but treated with 
GCV also proliferated rapidly and to nearly the same levels. On the other hand, GCV 
treatment resulted in over 95% cell death of AAV-3S5-infected cells (Fig. 14). Moreover, 
less than 65% of the remaining AAV-3S5/GCV-treated cells were viable as compared to 
over 95% viability of untreated control cells as assayed by trypan blue staining (data not 
shown). These results demonstrate that TK is expressed to levels high enough to sensitize 
PV harboring cells to killing by GCV treatment. 
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3.4  DISCUSSION 
We have developed a DNA recombination-based approach to eliminate PV 
infection. The efficacy of this approach is dependent on the ability of recombination to 
promote the expression of a suicide TK gene specifically in cells containing PV 
sequences. Using a variety of TK constructs, we demonstrate that TK expression can be 
specifically induced in PV-positive cells presumably as a result of homologous 
recombination between the cloned PV sequences with those present in the 
transfected/infected cells. This approach is expected to result in TK expression only in 
those cells in which a double crossover recombination event has occurred, resulting in 
reconstitution of the expression cassette. Single recombination events will not generate a 
functional transcription unit, and therefore are not expected to result in TK expression. 
The expression of many natural genes is known to be regulated by alternative 
poly(A) site selection and depends upon both the position and relative strength of the 
poly(A) sites (reviewed in Edwards-Gilbert et al, 1997). Among identical poly(A) 
signals, the 5' site is favored over a more distal downstream site (Demone & Cole, 1988).  
Also, when a strong poly(A) site precedes a weak one by a short distance, less than 5% of 
the processed mRNAs terminate at the weak site (Batt et al, 1994).  It was somewhat 
surprising; therefore, that TK expression in SS2TP was comparable to S2.1TP with the 
inclusion of strong upstream polyadenylation sites (Fig. 10). Cooke et al (1999) have 
shown that a 5' splice site, if not followed by a 3' splice site, can interfere with 
downstream polyadenylation. This interference may explain the high expression of TK by 
SS2TP. To eliminate this possibility, a 3' splice site was introduced upstream of the SV40 
polyadenylation sites to create 3S3. The low levels of expression seen in 3S3 (Fig. 10) 
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may be due to splicing between 5' ss I and 3' ss I in a mechanism similar to exon 
skipping. Exon skipping has been shown to decrease when the 5' splice site following the 
skipped exon is strengthened, but increases when the 5' splice site is weakened or 
eliminated (Kuo et al, 1991).  3S3 contains no 5' splice site following the SV40 poly(A) 
signals, so one was introduced to create 3S35, which does not express TK (Fig. 10). 
We have utilized alternative poly(A) site selection as a means to regulate the 
expression of a suicide gene, TK, in cell lines. TK expression cassettes were developed in 
which strong SV40 poly(A) site(s) are surrounded by BPV-1 sequences (Fig. 9). 
Furthermore, the BPV-1 sequences are surrounded by 5' and 3' splice sites, respectively. 
Transcription initiated from the upstream SV40 early promoter is expected to generate a 
primary transcript, which will be spliced utilizing 5' ss 1 and 3' ss II, resulting in the 
termination of transcription and polyadenylation at the SV40 poly(A) site. Since the 
HSV-1 TK gene is located downstream of this region (Fig. 9), little or no expression of 
the TK gene is expected. This was indeed the case when the COS-1 cell line was 
transfected with the 3S35 vector (Fig. 10 & 11). These results suggest that proper 
placement of the poly(A) sites as well as 5' and 3' splice sites in 3S35 promotes efficient 
transcription termination, and therefore no detectable TK expression. We included two or 
three copies of the SV40 poly(A) sequence in some constructs since multiple copies of 
this sequence were previously found to block spurious transcription in a plasmid 
containing a promoter-less reporter gene (Maxwell et al, 1989).  
We tested whether homologous recombination can be used as a means to promote 
TK expression exclusively in PV-positive cells. For this, we cloned a 2.1-kb region of the 
BPV-1 L1 and L2 ORFs (nt positions 4501−6647) into the various constructs. 
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Furthermore, the SV40 poly(A) sequence was inserted in the middle of the above region 
such that the upstream BPVa region consisted of 926 bp, while the downstream BPVb 
region contained 1169 bp (Fig. 9). The above region of the BPV-1 genome contains no 
known promoter element, and contains only part of the L1 and L2 ORFs and so it is not 
expected to express any protein. We hypothesized that when the above constructs are 
present in BPV-positive cells, homologous recombination between the L1/L2 regions 
present in the constructs and the BPV-1 genome in cells would result in deletion of the 
SV40 poly(A) sequence and regeneration of a TK expression cassette in which the 
polyomavirus poly(A) site present downstream of the TK gene is used for the termination 
of transcription (Fig. 9). Western blot analysis of COS-1 cells cotransfected with the 3S35 
and a BPV-1-containing plasmid showed expression of TK (Fig. 12). Since no TK was 
expressed in the absence of the BPV-1 plasmid (Fig 8), these results suggest that the most 
likely mechanism for the induction of TK expression involves homologous 
recombination between the L1/L2 regions of the two plasmids. This possibility is further 
supported by the slight increase in TK expression when the recombination target BPV-1 
plasmid was linearized prior to transfection (Fig. 12). Homologous recombination is 
known to increase when one of the recombination substrates has linear ends (Ayers et al, 
1985). 
For a therapeutic expression cassette to be useful in vivo, an effective vector must 
be used for delivery. AAV is an ideal viral vector for this application since it commonly 
infects humans, but is not known to cause any human disease (Xiao et al, 1998).  It has 
the ability to infect efficiently many types of dividing and nondividing cells (Xiao et al, 
1998).  Wild-type AAV-2 has also been found in significant numbers of cervical 
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epithelial cells from patients, indicating that AAV can infect cells harboring mucosa-
tropic HPVs (Venturoli et al, 2001).  Our experiments using the AAV-3S5 construct 
showed that TK is expressed in BPV-positive cells but not in BPV-negative cells (Fig. 
13b). These results suggest that homologous recombination between the L1/L2 sequences 
in the TK cassette and the BPV-1 genome results in the expression of the TK gene 
specifically in BPV-1-positive cells. 
The results of our studies demonstrate that homologous recombination can be 
used as a means to express a suicide gene, TK, in virally infected cells. Such cells are 
then sensitive to treatment with the well-established anti-herpesvirus drug GCV allowing 
elimination of over 95% of PV-infected cells (Fig. 14). This will allow us to develop a 
strategy in the future to eliminate specifically HPV-infected cells using GCV. Also, due 
to the well-known 'bystander effect' of TK, HPV-positive cells within a lesion that are not 
infected by the TK cassette are also likely to be eliminated by GCV treatment. An 
approach to eliminate PV-infected cells has been described by Sethi and Palefsky (2003), 
whereby TK expression is transcriptionally regulated by the presence of the viral E2 
protein. We have developed an entirely different approach in which only the presence of 
viral DNA is required for TK expression. 
Many high-risk HPVs such as types 16 and 18 are associated with the 
development of cancer of the cervix and oral cavity (Dell & Gaston, 2001; Stubenrauch 
& Laimins, 1999; Fehrmann & Laimins, 2003; zur Hausen, 2002).  Frequently, the HPV 
DNA is integrated into the genome in cancers which express the viral E6 and E7 
oncogenes to high levels(Dell & Gaston, 2001; Stubenrauch & Laimins, 1999; Fehrmann 
& Laimins, 2003; zur Hausen, 2002).  The mechanisms and/or events that promote 
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integration of the HPV genome are not well known. Therefore, any approach for the 
elimination of high-risk HPVs from infected cells will have to be carefully developed so 
as not to promote integration of the viral DNA into the genome. However, low-risk HPVs 
such as types 6 and 11 cause long-term infections and painful lesions but are rarely 
associated with the development of cancers (Dell & Gaston, 2001; Stubenrauch & 
Laimins, 1999; Fehrmann & Laimins, 2003; zur Hausen, 2002).  Their inability to 
promote malignant transformation is primarily due to the fact that their E6 and E7 
oncoproteins do not inactivate the functions of the cellular tumor suppressor proteins 
such as p53 and pRB (Dell & Gaston, 2001; Stubenrauch & Laimins, 1999; Fehrmann & 
Laimins, 2003; zur Hausen, 2002).  Thus, the strategy described in this report can be 
readily adapted for the treatment of lesions caused by low-risk HPVs. Also, since TK 
expression is limited to infected cells, this approach is likely to have little effect on 
uninfected cells. Finally, our recombination approach may also be potentially useful for 
the elimination of other viral infections. 
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Chapter 4 
 
GENERAL DISCUSSION 
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4.1  CHARACTERIZATION OF TRANSCRIPTION FACTORS BINDING TO 
HPV-16 DURING CELLULAR DIFFERENTIATION 
 
We have used the W12 clone 20863 to identify changes in TF binding to HPV 
during host cell differentiation.  This cell line harbors HPV-16 episomally (Fig. 5) and 
can be induced to differentiate using standard techniques (Fig. 6).  We used the Panomics 
transcription factor array to characterize the many changes in transcription factor binding 
during differentiation in this cell line.  This analysis shows that the levels/DNA binding 
activity of more than 150 TFs changes during differentiation, out of approximately 345 
TFs (Fig. 7).  We also modified this technique to identify which of these transcription 
factors bind HPV-16, as well as to identify factors that bind known promoter regions.  
With this methodology, we have identified over 30 factors which may be involved in 
HPV-16 transcription (Fig. 7).   
 Many of these factors, such as C/EBP alpha, NF-1 and YY1, have been shown to 
interact with HPV-16 previously (Ai et al, 1999; Chan et al, 1990; Ciccolini et al, 1994; 
Gloss & Bernard, 1990).  These known factors represent positive controls and partially 
validate the unknown factors identified by this analysis.  Many other factors, such as 
NFkB, and Stat5, have been loosely associated with HPV infection or HPV related 
malignancies, but were not known to be directly involved in transcription of the viral 
genome (Bodily & Meyers, 2005; Hirokawa et al, 2003).  These data may represent a 
mechanism by which these associated factors may affect papillomavirus expression 
during maturation or carcinogenesis.  The majority of identified factors, such as C-Myb, 
Pax5, NF-ATx and WT1, represent novel interactions between transcription factors and 
the HPV-16 genome.  Many transcription factors identified by this analysis, such as 
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C/EBP alpha, C-Myb, NF-ATx, and Pax5 have known roles in development and/or 
differentiation (Gloss & Bernard, 1990; Hadaschik et al, 2003; O’Conner et al, 2000; 
Rocha-Zavaleta et al, 2004).  We expected changes in binding of many TF’s involved in 
differentiation to change during the induction of the process of terminal differentiation in 
epithelial cells.  Some identified transcription factors, such as NFkB and WT1, have been 
associated with cancers (Grassmann et al, 1996; Hebner & Laimins, 2005).  A few 
identified transcription factors, such as NF-1, are involved in the transcription of a wide 
variety of promoters in many cell types under many conditions.  While others, such as 
STAT5, activate promoters under more specific conditions (Hadaschik et al, 2003).  
 In order to validate data obtained from these arrays, a few genes of each class 
were further analyzed using consensus binding sequences obtained from the TRANSFAC 
database (Wingender et al, 2000).  These binding sites were compared to the Pst-I 
fragment of HPV-16 which contains all putative promoters.  Not all TF’s identified by 
the Panomics array have identifiable binding sites in this region (data not shown).  The 
majority of transcription factors have binding sites that map to known or putative 
promoter regions (Fig. 8).  Of these factors, most binding sites map to regions associated 
with late gene expression.  These poorly characterized promoters are thought to be 
dramatically upregulated during host cell differentiation as compared to the modest 
upregulation observed in the p97 promoter (Fehrmann & Laimins, 2003; Nees et al, 
2001).   
 We have further validated binding as well as quantified increases in binding for 
these transcription factors using ChIP assays.  These ChIP assays demonstrate that all 
TF’s investigated bind HPV-16, and that binding increases in all factors upon 
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differentiation.  In the transcription factors C/EBP alpha, C-Myb and NF1, binding 
increased by 8 fold or more.  NF-ATx and Pax5 showed modest increases of about 2.6 
and 1.9 fold, respectively.  STAT5 and WT1 showed small but reproducible increases in 
binding of about 1.5 fold.  This represents the first in vivo evidence that some of these 
factors bind HPV. 
 We have also used Western blot analysis to determine if increases in TF binding 
correspond to further validate increases in various TF at the protein level during 
differentiation.  We see large increases in C-Myb and NF-1 protein levels during 
differentiation, which corresponds to large increases in viral binding as determined by 
ChIP assay and oligonucleotide binding as determined by Panomics array.  The C/EBP 
alpha protein was substantially increased during differentiation, which matched well with 
the 7.6 fold increase in oligonucleotide binding and the 8.0 fold increase in viral binding.  
The STAT5 protein was also consistent across all analyses with a modest increase in the 
level of active phosphorylated STAT5 during differentiation, a 3.8 fold increase in 
oligonucleotide binding, and a small, but reproducible increase of 1.5 fold in viral 
binding.  Levels of Pax5 and WT1 protein are also increased dramatically during 
differentiation.  These data match well with the large increases seen in oligonucleotide 
binding as determined by Panomics array for Pax5 and WT1, but do not correlate 
strongly with the small increases in viral binding seen in the ChIP assay.  This could be a 
result of the saturation of one or more TF binding sites during differentiation.  For 
example, if half of the WT1 binding sites are occupied prior to differentiation, ChIP 
assays can detect a maximum of two-fold increase.  The two-fold increase reported by the 
ChIP assay may differ substantially from the drastic increases in expression or activity 
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reported by Western blot or Panomics array, but it reveals the same trend.  The NF-ATx 
protein was increased only slightly during differentiation as assayed by western blot, 
which contrasts with the dramatic increases by Panomics array and ChIP assay.  This 
could be due to differences in the nuclear localization of NF-ATx, as NF-ATx activity is 
known to be regulated in this manner (Rocha-Zavaleta et al, 2004). 
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 4.2  FUTURE DIRECTIONS IN THE STUDY OF HPV-16 TRANSCRIPTION 
In the future, we plan to investigate the functional consequences of the TF/HPV 
interactions outlined in Chapter 3.  We are currently in the process of creating reporter 
plasmids containing either the p97 or p670 promoters (see introduction) upstream of the 
luciferase reporter gene.  Since some TF binding sites upstream of bp 97 might effect 
transcription of the p670 promoter, we are also creating a reporter cassette including both 
the p97 and p670 promoters in which luciferase is inserted downstream of the p670 
promoter.  As we are primarily interested in the activity of the late promoter in this 
construct, we will mutate the upstream TATA box to prevent initiation at the p97 
promoter.  This technique was first used in HPV-31 to create a reporter representing the 
late promoter with all upstream transcription factor binding sites (Spink & Laimins, 
2005). These reporter plasmids will be transfected into HaCat cells (an HPV negative 
keratinocyte cell line), protein will be extracted before and after differentiation, and 
luciferase assays will be performed.  As reported previously, transcription from the p97 
promoter is expected to increase about 1.5 to 3 fold upon differentiation of the host cell 
(Apt et al, 1996; Grassmann et al, 1996; Yukawa et al, 1996).  The activity of the p670 
promoter, both short and full length, are expected to increase about 5-12 fold upon 
cellular differentiation (Grassmann et al, 1996; Rosensteirne et al, 2003).   
Once these basal levels of induction are established, a series of mutations will 
abolish TF binding sites throughout the full length p670 promoter.  We are interested in 
deleting the NF-1 sites in the full length p670 promoter.  This is expected to reduce the 
basal levels of transcription before and after differentiation (Ai et al, 1999).  The mutant 
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reporter may also exhibit a reduction in fold increase upon differentiation, which would 
be a strong indication that NF-1 is intimately involved in the regulation of viral gene 
expression.  We have planned similar experiments with reporter plasmids in which 
C/EBPα, STAT5, C-Myb, and WT-1 sites are abolished.  Following transfection, any 
reduction in the fold induction upon differentiation is a strong indication of the 
involvement of that particular factor in control of the life cycle of HPV-16.  Additionally, 
we are planning to cotransfect the p97 and p670 promoters along with cassettes 
expressing various TFs.  We expect to see an increase in luciferase expression if a 
particular TF stimulates transcription from these promoters.  The overexpression of some 
factors may not result in an increase in p97/p670 expression, due to a variety of factors, 
but any increases in transcription are indications of the importance of TF binding.  In 
order to further confirm binding of some of these factors, we also wish to overexpress 
and purify various TF proteins and test their binding to putative binding sites in wt 
promoters by EMSA.  This type of confirmatory experiment will be especially important 
for factors with no previously known HPV involvement, such as C-Myb, STAT5, Pax5, 
and WT-1.  
Recently, it has been shown that HPV DNA is methylated in vivo (Kalantari et al, 
2004).  We are interested in identifying functional consequences of this methylation and 
elucidating the role of methylation in the HPV life cycle.  All seven NF-1 binding sites 
contain GC pairs which may be methylated and the Pax5 binding site contains four GC 
pairs.  In order to determine if these sites may play a role in transcriptional regulation, we 
are planning to use bisulfite sequencing to determine if these sites are methylated in vivo 
and if this methylation pattern changes during differentiation.  If a particular GC pair is 
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found to be differentially methylated, we plan to perform competitive EMSAs with both 
methylated and unmethylated substrates to determine if methylation affects the affinity of 
the TF towards DNA.  We also plan to mutate the particular GC pairs in the previously 
mentioned p97 and p670 luciferase reporter cassettes and use transfection to determine 
the effect of these mutations on transcription. 
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4.3  OUTLOOK ON A RECOMBINATION-BASED APPROACH TO 
ELIMINATE PAPILLOMAVIRUS INFECTION 
Stratagem 
We have developed a DNA recombination-based approach to eliminate PV 
infection.  This system enables the use of an untargeted viral vector, AAV, to deliver the 
cassette in vivo.  Using a variety of TK constructs, we have demonstrated that TK 
expression can be specifically induced in PV-positive cells.  The nature of the expression 
cassette limits TK expression to cells in which homologous recombination occures 
between segments of the viral genome and the expression cassette. As shown in Fig. 15, a 
recombinatorial event resulting in removal of the premature polyadenylation site and 
flanking splice sites results in alternative polyadenylation site selection and alternate 
splicing and leads to TK expression.  In order to have specificity of the induction of TK, 
only the result of a double cross-over homologous recombination event or a gene-
conversion event is designed to express TK.  These and other likely products of DSB 
repair are evaluated case by case below for 3S35-based expression cassettes to illustrate 
the basis and rational of this strategy. 
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Case 1: No recombination 
 
If there is no recombination, there will be no TK expression.  Transcription is 
initiated at the SV40 promoter.  Splicing occurs between 5’ splice site I and 3’ splice site 
II to remove the BPVa region, and polyadenylation occurs at one of the SV40 poly(A) 
signals.  As mentioned in the introduction, the SV40 poly(A) sites are favored over the 
downstream polyomavirus poly(A) site as a result of the strength of the sites, the distance 
to the polyomavirus site, and the placement of the splice sites.  The TK ORF will not be 
included in the resulting message, and no TK will be expressed.  This is confirmed by 
Northern and Western blot analysis shown in Fig. 10 & 11. 
 
Case 2: Double cross-over homologous recombination between BPV-derived regions 
and the BPV genome 
 
If the expression cassette and the BPV genome are both present in the cell, a 
double cross-over homologous recombination event or other gene conversion event can 
occur between homologous regions in the introduced expression cassette and the BPV 
genome.  This can trigger TK expression.  In the recombined construct, the SV40 poly(A) 
signal will be removed from the construct so that the BPV regions are continuous.  
Transcription in this cassette (modeled as S2.1TP) starts at the SV40 promoter.  Splicing 
occurs between 5’ splice site I and 3’ splice site II, removing BPV derived regions from 
the resulting transcript.  Transcription also proceeds through the TK ORF, and the 
polyomavirus polyadenylation signal is utilized.  This pattern of expression is confirmed 
by Northern and Western blot analysis shown in Fig. 10 & 11. 
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Case 3: Single cross-over homologous recombination events between the expression 
cassette and BPV genome 
 
Constructs that recombine at a single site will not express TK since the SV40 
promoter will be separated from the TK ORF.  It would be attractive to trigger TK 
expression through single cross-over, since these events will be specific to PV infected 
cells and will have a higher frequency than the double cross-over events.  However, it is 
difficult to design strategies that trigger TK expression from a cassette as a result of a 
single cross-over event.  Recombination events of this type create fusions of the 
introduced expression cassette and the PV genome with PV sequences either upstream or 
downstream (depending on the design) of the TK ORF.  One way in which this could 
trigger TK expression is that downstream PV sequences might be chosen that contain a 
poly(A) signal which could replace plasmid sequences containing a strong poly(A) 
signal.  Because weak poly(A) signals still result in substantial expression, this change is 
not likely to tightly regulate TK expression.  Alternatively, a single cross-over event 
might be designed to replace plasmid sequences upstream of the TK ORF with PV 
sequences.  If the plasmid sequence undergoing recombination did not have a strong 
promoter activity (and the PV sequence contained a strong promoter) the recombined 
expression cassette would express more TK than the expression cassette prior to 
recombination.  Unfortunately, the strongest PV promoter is much weaker than the strong 
CMV or SV40 promoters used in mammalian expression cassettes.  Also, an expression 
cassette designed to trigger TK expression when under the control of a strong promoter 
might not be highly specific to PV infected cells.  A cassette of this type could integrate 
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through non-homologous recombination into the host cell genome behind a strong 
promoter.  These types of events are fairly common in many cell types, and would lead to 
TK expression from PV-negative cells, resulting in a loss of specificity. 
 
 
Case 4: Nonhomologous recombination involving the expression cassette and the 
host cell genome 
 
Since nonhomologous recombination events do not require extensive homology, 
any sequence from the expression cassette that picks up a DSB could be repaired by 
ligation (by either single-stranded annealing or nonhomologous end-joining mechanisms) 
to virtually any genomic sequence.  This could yield either partial or whole inclusions of 
the expression cassette in the genome of the cell.  Partial inclusions of the transcriptional 
unit would likely not express TK, as they would separate the SV40 promoter from the TK 
ORF.  Likewise, whole inclusions of the transcriptional unit will not express TK, as the 
premature SV40 poly(A) site will be preferred.   
It should be noted that a nonhomologous recombination event resulting in the 
insertion of the TK ORF (lacking promoter/regulatory sequences) downstream of an 
active promoter could result in TK expression in PV-negative cells.  As PV-negative cells 
infected or transfected with the non-expressing cassette do not express detectable levels 
of TK, we can conclude that this type of event is very rare.  Consequently, although this 
type of event remains a theoretical possibility, we are still confident that very, very few 
PV-negative cells will express TK by this mechanism.   
Random integration of rAAV in various places throughout the host cell genome 
does have the potential to disrupt the expression of tumor suppressors and has some 
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limited oncogenic potential.  This is a very real safety concern.  It should be noted that 
there is no record of rAAV or wt AAV causing cancer, even though most people are 
seropositive for at least one type of AAV.  HPV, on the other hand, has a very strong and 
well documented association with cancer.  In summary, the risk of using a virus like 
rAAV to eliminate PV infection, while not zero, is lower than the risk of continued high 
risk HPV infection.   
 
 
Case 5: Nonhomologous recombination events within the expression cassette 
 
Events of this type will create deletions and junctional aberrations in the 
expression vector.  Most deletions will not result in TK expression, such as a deletion in 
the SV40 promoter, 5’ splice site I, or the TK ORF, etc.  A deletion in the SV40 poly(A) 
signals without deletions in 5' splice site I or 3' splice site II will result in TK expression 
for the same reasons listed in Case 2.  This type of event would occur in cells 
infected/transfected with TK expression cassette in PV-negative cells, Fig. 10 & 11 
confirm that this event is undetectable. 
 
Design of expression cassettes 
We have utilized alternative poly(A) site-selection as a means to regulate the 
expression of a suicide gene, TK, from a gene cassette in cell lines.  The desirable 
features of this gene cassette are that it must not express TK, but in the presence of PV 
sequences in the cell, it should undergo homologous recombination leading altered 
poly(A) signal usage and TK expression.  The expression of many natural genes is known 
to be regulated by alternative poly(A) site selection and this selection is known to be 
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dependent on both the position and relative strength of the poly(A) sites (reviewed in 
section 1.5).  Among identical poly(A) signals, the 5' site is favored over a more distal 
downstream site (Batt et al, 1994).  Also, stronger poly(A) sites can be used with much 
higher frequency, whether they are upstream or a short distance downstream of the 
weaker site. 
We generated the SS2TP expression cassette (Fig. 9) to take advantage of these 
known criteria for poly(A) site selection.  In this expression cassette, an intron containing 
segments of the BPV genome was inserted upstream of the TK ORF and the weak late 
poly(A) site of polyomavirus (Batt et al, 1994).  Two SV40 poly(A) sites were then 
inserted into the middle of the above BPV sequence (Fig. 9). We anticipated that 
transcripts from this expression cassette would primarily terminate at the strong upstream 
SV40 poly(A) sites.  It was somewhat surprising; therefore, that TK expression in SS2TP 
was comparable to S2.1TP even with the inclusion of strong upstream polyadenylation 
sites (Fig. 10 & 11).   
Cooke et al (1999) have shown that a 5' splice site, if not followed by a 3’ splice 
site, can interfere with downstream polyadenylation.  This interference may explain the 
high expression of TK by SS2TP.  To eliminate this possibility, a 3’ splice site was 
introduced upstream of the SV40 polyadenylation sites to create 3S3.  The low levels of 
expression seen in 3S3 (Fig. 10) may be due to splicing between 5’ ss I and 3’ ss I in a 
mechanism similar to exon skipping.  Exon skipping has been shown to decrease when 
the 5' splice site following the skipped exon is strengthened, but increases when the 5' 
splice site is weakened or eliminated (Kuo et al, 1991).  3S3 contains no 5’ splice site 
following the SV40 poly(A) signals, so one was introduced to create 3S35, which does 
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not express TK (Fig. 10).  These results suggest that proper placement of the poly(A) 
sites as well as 5’ and 3’ splice sites in 3S35 promotes efficient transcription termination, 
and therefore no detectable TK expression. 
 
Ability to regulate TK expression upon cotransfection  
We tested whether homologous recombination can be used as a means to promote 
TK expression exclusively in PV-positive cells. For this, we cloned a 2.1-kb region of the 
BPV-1 into the various constructs for use as a recombination target and cotransfected this 
construct along with the 3S35 plasmid.  We hypothesized that when the above constructs 
are present in BPV-positive cells, homologous recombination could occur between the 
BPV derived regions present in the constructs.  This recombination could result in 
deletion of the SV40 poly(A) sequence and result in a TK expression cassette in which 
the downstream polyomavirus poly(A) site is used, and TK is expressed.  Western blot 
analysis of COS-1 cells cotransfected with 3S35 and a BPV-1-containing plasmid showed 
expression of TK (Fig. 12). Since no TK was expressed in the absence of the BPV 
derived sequences (Fig. 12), these results suggest that TK expression involves 
homologous recombination between the L1/L2 regions of the two plasmids as designed. 
This possibility is further supported by the slight increase in TK expression when the 
recombination target BPV-1 plasmid was linearized prior to transfection (Fig. 12). 
Homologous recombination is known to increase when one of the recombination 
substrates has linear ends (Ayers et al, 1985). 
Effective inhibition of replication in tissue culture cells harboring BPV is 
fundamentally a function of the number of cells in which a productive recombinatorial 
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event takes place and subsequently express TK.  This number of cells is of particular 
concern because it represents the minimum number of infected cells in which replication 
will be inhibited by ganciclovir treatment.  The actual number of inhibited cells is likely 
to be somewhat higher because phosphorylated versions of ganciclovir can leak through 
gap junctions from cells that express TK to prevent replication in neighboring cells 
(Dilber et al, 1997).   It is, however, potentially interesting to determine the percentage of 
cells that express TK in our cotransfection system (Fig. 12), as well as the percentage of 
plasmids which have undergone recombination in the same system.  Work attempting to 
quantify the percentage of recombined expression cassettes in this cotransfection system 
has not been highly informative thus far.  These assays were performed by first isolating 
low-molecular weight DNA from co-transfected and control cells through Hirt 
fractionation (Hirt, 1967).  Southern Blots were performed directly on these Hirt 
fractions, but the results were inconclusive, as recombinant digestion patterns were 
obscured by the vast excess of unrecombined plasmids (data not shown).  Because the 
recombined expression cassette acts as plasmid, these Hirt fractions were then used to 
transform E. coli, and plasmid DNA from the mixed population of transformed bacteria 
was harvested.  This plasmid DNA was then digested with a restriction enzyme designed 
to digest the unrecombined plasmid, but leave the recombined plasmid intact.  Fresh E. 
coli was transformed with this digested DNA, individual clones were isolated, and their 
plasmid DNA was screened for similarity to the predicted recombination product.  This 
process has yielded plasmids which match recombined plasmid, according to restriction 
enzyme analysis.  This process cannot, however, determine the frequency of 
recombination and was not pursued in depth. 
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 Ability to Regulate TK Expression when Delivered by AAV 
  For a therapeutic expression cassette to be useful in vivo, an effective vector must 
be used for delivery. AAV is an ideal viral vector for this application since it commonly 
infects humans, but is not known to cause any human disease (Hirata & Russel, 2000).  It 
has the ability to infect efficiently many types of dividing and nondividing cells (Hirata & 
Russel, 2000).  Wild-type AAV-2 has also been found in significant numbers of cervical 
epithelial cells from patients, indicating that AAV can infect cells harboring mucosa-
tropic HPVs (Venturoli et al, 2001).  Our experiments using the AAV-3S5 construct 
showed that TK is expressed in BPV-positive cells but not in BPV-negative cells (Fig. 
13b). These results suggest that homologous recombination between the L1/L2 sequences 
in the TK cassette and the BPV-1 genome results in the expression of the TK gene 
specifically in BPV-1-positive cells. 
 The results of our studies demonstrate that homologous recombination can be 
used as a means to express a suicide gene, TK, in virally infected cells. Such cells are 
then sensitive to treatment with the well-established anti-herpesvirus drug GCV, allowing 
elimination of over 95% of PV-infected cells (Fig. 14). This will allow us to develop a 
strategy in the future to eliminate specifically HPV-infected cells using GCV. Also, due 
to the well-known 'bystander effect' of TK, HPV-positive cells within a lesion that are not 
infected by the TK cassette are also likely to be eliminated by GCV treatment.  
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An approach to eliminate PV-infected cells has been described by Sethi and Palefsky 
(2003), whereby TK expression is transcriptionally regulated by the presence of the viral 
E2 protein. We have developed an entirely different approach in which only the presence 
of viral DNA is required for TK expression. 
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4.4  FUTURE OF RECOMBINATION-BASED APPROACHES TO 
ELIMINATE VIRAL INFECTIONS 
 
Many high-risk HPVs such as types 16 and 18 are associated with the 
development of cancer of the cervix and oral cavity (Dell & Gaston, 2001; Stubenrauch 
& Laimins, 1999; Fehrmann & Laimins, 2003; zur Hausen, 2002).  Frequently, the HPV 
DNA is integrated into the host cell genome in late stage cancers associated with these 
viruses (Dell & Gaston, 2001; Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 
2003; zur Hausen, 2002).  Low-risk HPVs such as types 6 and 11 cause long-term 
infections and painful lesions, but are rarely associated with the development of cancers 
(Dell & Gaston, 2001; Stubenrauch & Laimins, 1999; Fehrmann & Laimins, 2003; zur 
Hausen, 2002).  Because the recombination based approach described is likely to not be 
capable of eliminating PV-positive cells in which the viral genome is integrated, this 
strategy would be best adapted for the treatment of lesions caused by low-risk HPVs or 
very early stage high-risk types.  Also, since TK expression is limited to infected cells, 
this approach is likely to have little effect on uninfected cells. Finally, our recombination 
approach may also be potentially useful for the elimination of other viral infections.   
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In order to validate that the system can be adapted to other viruses, we plan to 
move the system from a BPV system into a HPV system.  This involves the replacement 
of the BPV recombination regions (Fig. 9) with HPV sequences.  These HPV sequences 
must not contain promoter elements, splice sites, or polyadenylation signals, as these may 
interfere with the regulatory mechanism.  This construct would be tested in a 
cotransfection system (as with BPV) prior to the creation of a rAAV to deliver the 
construct.  rAAV would also be used to deliver the therapeutic cassette into HPV positive 
cells and TK expression and activity would be assayed. 
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